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A B S T R A C T
Background
Drooling is a common problem for children with cerebral palsy (CP). This can be distressing for these children as well as for their parents
and caregivers. The consequences of drooling include risk of social rejection, damp and soiled clothing, unpleasant odour, irritated
chapped skin, mouth infections, dehydration, interference with speech, damage to books, communication aids, computers, and the risk
of social isolation (Blasco 1992; Van der Burg 2006). A range of interventions exist that aim to reduce or eliminate drooling. There is
a lack of consensus regarding which interventions are most effective for children with CP.
Objectives
(1) To evaluate the effectiveness and safety of interventions aimed at reducing or eliminating drooling in children with cerebral palsy.
(2) To provide the best available evidence to inform clinical practice. (3) To assist with future research planning.
Search methods
We searched the following databases from inception to December 2010 : Cochrane Central Register of Controlled Trials (CENTRAL);
Medline via Ovid; EMBASE; CINAHL; ERIC; Psych INFO; Web of Science; Web of Knowledge; AMED; SCOPUS; Dissertation
Abstracts.
We searched for ongoing clinical trials in the Clinical Trials web site (http://clinicaltrials.gov.) and in the Current Controlled Trials web
site (http://www.controlled-trials.com/). We hand searched a range of relevant journals and conference proceeding abstracts.
Selection criteria
Only randomised controlled trials (RCTs) and controlled clinical trials (CCTs) were included.
Data collection and analysis
Data were extracted independently by MW, MS and LP and differences resolved through discussion.
Main results
Six studies were eligible for inclusion in the review. Four of these studies were trials using botulinum toxin-A (BoNT-A) and two were
trials on the pharmacological interventions, benztropine and glycopyrrolate. No RCTs or CCTs were retrieved on surgery, physical,
oro-motor and oro-sensory therapies, behavioural interventions, intra-oral appliances or acupuncture. In the studies eligible for review,
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there was considerable heterogeneity within and across interventions and a meta-analysis was not possible. A descriptive summary of
each study is provided. All studies showed some statistically significant change for treatment groups up to 1 month post intervention.
However, there were methodological flaws associated with all six studies.
Authors’ conclusions
It was not possible to reach a conclusion on the effectiveness and safety of either BoNT-A or the pharmaceutical interventions,
benztropine and glycopyrrolate. There is insufficient evidence to inform clinical practice on interventions for drooling in children with
CP. Directions for future research are provided.
P L A I N L A N G U A G E S U M M A R Y
Interventions for drooling in children with cerebral palsy
Many children with CP have difficulty controlling saliva. Drooling varies in severity and can be distressing for the children, families
and caregivers. Excessive drooling can cause constant damp soiled clothing, unpleasant odour, irritated, chapped or sore skin around
the mouth and chin, skin and mouth infections, dehydration, difficulties chewing, interference with speech, damage to books, com-
munication aids, computer and audio equipment. There is also risk of social rejection and social isolation for these children.
Many interventions are used to reduce or eliminate drooling. These include surgery, medications, botulinum toxin (BoNT-A and
BoNT-B)), physical therapies, therapies to improve sensory function, behavioural therapies to assist the child in managing his/her own
drooling, appliances placed in the mouth, and acupuncture.
There is no clear consensus on which interventions are safe and effective in managing drooling in children with CP. This makes it hard
to decide which intervention will be safest and most effective.
Only RCTs and CCTs were included in this review. Trials were identified by electronic searches of databases, searches of clinical trials
registers, peer reviewed journals, published conference proceedings and reference lists of relevant articles.
Six trials were found. Four examined the safety and efficacy of BoNT-A and two examined benztropine and glycopyrrolate. No trials
were found on other interventions. The quality of trials was variable. The trials all differed in the children recruited, the product used,
how the product was delivered and how its effectiveness was measured. All trials reported a positive reduction in drooling and all showed
some statistically significant change for treatment groups up to 1 month post intervention. Few studies examined client and/or carer
satisfaction with the intervention. Some looked at side effects of the intervention but no study examined the effect of interventions on
the child’s quality of life or psychological well being.
There is insufficient evidence to support the use of one intervention over another. As trials on just two kinds of interventions were
retrieved, and given the variation and quality of these studies, it is not possible to conclude that one intervention is more effective than
another. The lack of trials on other interventions does not suggest that these interventions are ineffective.
Adequately powered well designed trials are required across all interventions. In addition to using sensitive measures looking at change
in salivary flow, measures are needed that examine client and carer satisfaction, changes in quality of life, psychological well being and
in unwanted symptoms associated with drooling.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Outcome Study N in Control/Treatment Standardized mean difference
(SMD) where calculable
Mean values are multiplied by -
1 where relevant to correct for
differences in the direction of the
scale
Quality of the Evidence (GRADE) Comments
Reduction in salivary flow Jongerius 2004b 39 Cross-over trial
(39/39)
Swab Method as Outcome Mea-
sure
(0-2 weeks)
Scopolamine/BoNT-A
Mean differences: 0.0725 (SD =
0.13)
p<0.05*
SMD = 0.56,
(4 Weeks)
Scopolamine/BoNT-A
Mean differences: 0.0607 (SD =
0.15)
p<0.05*
SMD = 0.40,
(8 Weeks)
Scopolamine/BoNT-A
Mean differences: 0.0828 (SD =
0.13)
p<0.05*
SMD = 0.64,
(16 weeks)
Scopolamine/BoNT-A
Mean difference: 0.0371 (SD =
0.15)
p>0.05
SMD = 0.25,
(24 weeks)
Scopolamine/BoNT-A
Low Uncertainty re risk of bias (see
Figure 1)
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Mean difference: 0.0258 (SD =
0.16)
p>0.05
SMD = 0.016.
Lin 2008 7/6 Method Unknown
Baseline
BoNT-A/Placebo
Mean difference 2.45/2.86
p>0.05
SMD = 0.38
(0-2 weeks)
BoNT-A/Placebo
Mean difference:1.56/2.05
p>0.05
SMD = 0.58
(4 Weeks)
BoNT-A/Placebo
Mean difference: 1.38/2.15
p>0.05
SMD = 1.11
(6 Weeks)
BoNT-A/Placebo
Mean difference: 1.26/2.24
p<0.05*
SMD = 1.31
(8 Weeks)
BoNT-A/Placebo
Mean difference: 1.58/2.04
p>0.05
SMD = 0.48
(10 Weeks)
BoNT-A/Placebo
Mean difference: 1.40/2.11
p>0.05
SMD = 0.80
Low High risk of bias (see Figure 1)
Methods of measuring saliva
weight unknown
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(12 Weeks)
BoNT-A/Placebo
Mean difference: 1.10/1.87
p<0.05*
SMD = 1.14
(14 Weeks)
BoNT-A/Placebo
Mean difference: 1.49/1.95
p>0.05
SMD = 0.53
(18 Weeks)
BoNT-A/Placebo
Mean difference: 1.63/1.99
p>0.05
SMD = 0.46
(22 Weeks)
BoNT-A/Placebo
Mean difference: 1.58/2.21
p>0.05
SMD = 0.54
Reduction in frequency and
severity of drooling
Jongerius 2004a 39 Cross-over trial
(39/39)
DQ as Outcome Measure
(0-2 Weeks)
Baseline/Scopolamine
Mean difference:17.7 (SD = 21.
2))
p<0.001**
SMD = 0.83
(2 Weeks)
Baseline/BoNT-A
Mean difference:21.7 (SD = 18.
3)
p<0.001**
SMD = 1.18
Scopolamine /BoNT-A
Mean difference: 4.1 (SD =16.5)
p>0.05
Low Uncertainty re risk of bias (see
Figure 1)
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SMD = 0.25
(4 Weeks)
Baseline/BoNT-A
Mean difference:16.1 (SD = 18.
9)
p<0.001**
SMD = 0,85
Scopolamine/BoNT-A
Mean difference:-1.6 (SD = 19.
2)
p>0.05
SMD = -0.08
(8 Weeks)
Baseline/BoNT-A
Mean difference:20.0 (SD = 20.
5)
p<0.001**
SMD = 0.97
Scopolamine/BoNT-A
Mean difference:2.4 (SD = 21.7)
p>0.05
SMD= 0.11
(16 Weeks)
Baseline/BoNT-A
Mean difference:15.5 (SD = 19.
1)
p<0.001**
SMD = 0.81
Scopolamine/BoNT-A
Mean difference:-2.2 (SD = 21.
8)
p>0.05
SMD = -0.1
(24 Weeks)
Baseline/BoNT-A
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Mean difference:15.7 (SD = 16.
4)
p<0.001**
SMD = 0.96
Scopolamine/BoNT-A
Mean difference:-2.1 (SD = 20.
2)
p>0.05
SMD = -0.10
Lin 2008 7/6 DQ as Outcome Measure
Baseline
BoNT-A/Placebo
Mean difference 8.43/6.00
p>0.05
SMD = -0.80
(0-2 weeks)
BoNT-A/Placebo
Mean difference:2.67/6.71
p<0.01*
SMD = 2.4
(4 Weeks)
BoNT-A/Placebo
Mean difference: 5.17/9.29
p>0.05
SMD = 1.2
(6 Weeks)
BoNT-A/Placebo
Mean difference: 3.33/5.57
p<0.05*
SMD = 1.3
(8 Weeks)
BoNT-A/Placebo
Mean difference:1.83/6.86
p<0.01*
SMD = 1.7
(10 Weeks)
Low High risk of bias (see Figure 1)
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BoNT-A/Placebo
Mean difference: 3.50/6.57
p<0.05*
SMD = 1.2
(12 Weeks)
BoNT-A/Placebo
Mean difference: 4.00/5.00
p>0.05
SMD = 0.43
(14 Weeks)
BoNT-A/Placebo
Mean difference: 4.83/6.00
p>0.05
SMD = 0.55
(18 Weeks)
BoNT-A/Placebo
Mean difference: 5.83/5.29
p>0.05
SMD = -0.14
(22 Weeks)
BoNT-A/Placebo
Mean difference: 5.17/6.43
p>0.05
SMD = 0.36
Reid 2008 18/13 with CP DrI Scale as Outcome Measure
(0-2 weeks)
Not available
(4 weeks)
BoNT-A/No intervention
t = 5.697, p=0.001**
Mean difference: 27.38
CI for 95% significance = 17.44-
37.31
SMD = 2.04
No other data available for chil-
dren with CP
Low Limited data on children with CP
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Alrefai 2009 13/11 Thomas Stonell - Greenberg
Scale as Outcome Measure
(0-2 weeks)
Not available
(4 Weeks)
Placebo/BoNT-A
Median frequency score 4/3. p<0.
05*
Median severity score
5/4. p<0.05*
SMD not calculable from data
available
Low High risk of bias (Figure 1)
Lin 2008 7/6 Thomas Stonell - Greenberg
Scale as Outcome Measure
Baseline
BoNT/Control
Mean difference: 6.17/6.86
p>0.05
SMD = 0.54
(0-2 weeks)
BoNT-A/Placebo/
Mean difference: 5.33/6.29
p<0.05*
SMD = 1.21
(4 Weeks)
BoNT-A/Placebo
Mean difference: 5.17/6.71
p<0.01*
SMD = 1.8
(6 Weeks)
BoNT-A/Placebo
Mean difference: 5.00/6.29
p=0.05*
SMD = 1.24
(8 Weeks)
Low High risk of bias (see Figure 1)
9
In
te
rv
e
n
tio
n
s
fo
r
d
ro
o
lin
g
in
c
h
ild
re
n
w
ith
c
e
re
b
ra
l
p
a
lsy
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
2
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
BoNT-A/Placebo
Mean difference: 5.00/6.29
p=0.05*
SMD = 1.24
(10 Weeks)
BoNT-A/Placebo
Mean difference: 4.83/6.14
p>0.05
SMD = 0.86
(12 Weeks)
BoNT-A/Placebo
Mean difference: 5.00/6.43
p=0.05*
SMD = 0.87
(14 Weeks)
BoNT-A/Placebo
Mean difference: 5.33/6.57
p>0.05
SMD = 0.74
(18 Weeks)
BoNT-A/Placebo
Mean difference: 5.50/6.43
p>0.05
SMD= 0.45
(22 Weeks)
BoNT-A/Placebo
Mean difference: 5.67/6.43
p>0.05
SMD = 0.37
Adverse Effects to BoNT-A Alrefai 2009 13/11 2/11 (18%) children reported
transient increase in drooling at 2
weeks post treatment but not evi-
dent at one month post treatment
Low High risk of bias (See Figure 1)
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Jongerius 2004a 39/39
Cross-over trial
2/39 (5%) transient flu-like syn-
drome lasting <2 days
3/39 (8%) mild difficulty swal-
lowing
Low Uncertainty re risk of bias (see
Figure 1)
Reid 2008 18/13 with CP No information specific to chil-
dren with CP.
In treatment group in larger study
1/24 (4%) developed speech ,
swallowing and choking difficul-
ties in first 5 days
1/24 (4%) developed severe
chest infection on Day 5 post in-
jection
1/24 (4%) developed first seizure
2 days after injection
4/24 (17%) reported more vis-
cous saliva
’Some’’ reported Increased dif-
ficulty swallowing dry or hard
food*
Low
Lin 2008 7/6 None reported Low
Non-compliance with inter-
vention
Jongerius 2004a 6/39 (15%) withdrew from con-
trol arm of study.
4 children could not complete the
scopolamine period, 1 changed
antiepileptic medication and 1
was unable to attend for assess-
ments due to illness reported as
not related to the trial
Low
Alrefai 2009 8/24 (33%) withdrew from study,
6 from placebo and 2 from treat-
ment group
Reasons given are incomplete but
include lack of effect, distance for
children and carers to travel to
treatment centre and discomfort
associated with procedure
Low
1
1
In
te
rv
e
n
tio
n
s
fo
r
d
ro
o
lin
g
in
c
h
ild
re
n
w
ith
c
e
re
b
ra
l
p
a
lsy
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
2
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Lin 2008 Not reported Low
Reid 2008 Not reported specifically for chil-
dren with CP
Low
* = Statistically significant
** Wherever data have been published as p<0.000, these data have been reported as p<0.001.
*** In calculating the SMD, mean values are multiplied by -1 where relevant to correct for differences in the direction of the scale
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Cerebral palsy (CP) is defined by Bax 2005 as “a group of disor-
ders of the development of movement and posture, causing activ-
ity limitation, that are attributed to non-progressive disturbances
that occurred in the developing fetal or infant brain. The motor
disorders of cerebral palsy are often accompanied by disturbances
of sensation, cognition, communication, perception, and/or be-
haviour, and/or by a seizure disorder” (p.572). Drooling is a com-
mon problem for children with CP. For the purposes of this review,
we will define drooling as the unintentional loss of saliva from the
mouth (Blasco 1992; Reddihough 2010 ). Other definitions in-
clude: a visually evident presence of excessive saliva (Poling 1978),
saliva outside the lower lip (Lanconi 1989), spilling of saliva from
the mouth onto the lips, chin, neck and clothing (Brodsky 1993),
pools of saliva greater than one inch diameter (Kay 2006), saliva
(either a drop or a string) present beneath the lower lip line or a
string falling from themouth for a period longer than two seconds
without the individual cleaning his/her face and/or clothes (Van
der Burg 2009). Prevalence figures on drooling in children with
CP vary from37.4% (VanDeHeyning 1980) to 58% (Tahmassebi
2003a)
Drooling is generally not considered to be due to excessive produc-
tion of saliva or sialorrhoea (Tahmassebi 2003b)). It is more com-
monly associated with dysfunction of the oral phase of the swallow
with inadequate lip closure, disorganised tongue movements exac-
erbated by lack of oral and perioral sensory perception, head-down
posture, reduced frequency of swallowing and dysphagia (Nunn
2000; Senner 2004). In an international consensus statement on
drooling, Reddihough 2010 suggested a distinction between ante-
rior and posterior drooling for the purposes of understanding the
aetiology and impact of drooling. Anterior drooling is defined as
’saliva spilled from the mouth that is clearly visible’ (p.110) while
posterior drooling is described as saliva spilling through the faucial
isthmus creating a risk of aspiration.
Drooling can be distressing for children with CP, as well as for
their parents and/or caregivers. Reported side effects include: risk
of social rejection, constant damp and soiled clothing, unpleasant
odour, irritated chapped or macerated facial skin, perioral and
oral mouth infections especially candida albicans, dehydration,
impaired masticatory function, interference with speech, damage
to books, communication aids, electronic communication devices,
computers, audio equipment, and social isolation (Blasco 1992;
Van der Burg 2006). The associated dysphagia can increase the
risk of chest infections and aspiration pneumonia.
Description of the intervention
Amultidisciplinary team approach to themanagement of drooling
is advisable (McAloney 2005; Crysdale 2006; Reddihough 2010).
Teammembers can include neurologists, otolaryngologists, paedi-
atricians, plastic surgeons, speech and language therapists, paedi-
atric dentists, occupational therapists, psychologists, physiothera-
pists, nurses, and teachers. The following interventions are used
in the management of drooling in children with neurological im-
pairment.
(1) Surgery
Surgical intervention aims to either reduce or eliminate neural
stimulation to the salivary glands, to redirect saliva by rerouting
salivary flow, to block salivary flow and induce atrophy of the
glands through ligation or to eliminate the production of saliva
by excising the salivary glands. Surgical intervention can be per-
formedunilaterally or bilaterally and involves a general anaesthetic.
While each of the procedures below is described individually, pub-
lished studies report a combination of methods.
Surgical interventions include the following.
(a) Sectioning of the parasympathetic neural pathway. This typ-
ically involves either sectioning of the chorda tympani nerve
(Goode 1970) or tympanic neurectomy (Friedman 1974). The
chorda tympani nerve carries afferent fibres of taste from the ante-
rior two-thirds of the tongue and efferent parasympathetic nerve
fibres from the inferior salivary nucleus to the submandibular and
sublingual glands. Denervation works by eliminating parasympa-
thetic stimulation to the salivary glands. Adverse side effects in-
clude hearing loss and permanent taste loss in the anterior two-
thirds of the tongue as well as an increase in thickmucoid saliva. Its
advantage is that there are no external excisions to the face (Reed
2009; Scully 2009).
(b) Submandibular gland rerouting. This involves transferring the
submandibular ducts to approximately 1 cm behind the tongue
base, directing salivary flow posteriorly. It is contraindicated in
children with a history of aspiration pneumonia. Side effects in-
clude postoperative pain, ranula formation (i.e. pseudocysts on the
floor of the mouth), sialoadenitis (inflammation of salivary gland)
(Puraviappan 2007) secondary haemorrhage, lingual nerve palsy,
submandibular gland swelling, fibrosis at the site of the duct and
aspiration pneumonia (O’ Dwyer 1997).
(c) Submandibular gland ligation. This entails surgically tying the
salivary gland ducts. The salivary glands continue to produce some
saliva until atrophy occurs. This type of surgery is rarely carried out
in isolation as the saliva produced by these glands is more viscous
and more alkaline than that produced by the parotid glands. It
therefore increases the risk of developing submandibular salivary
gland stones due to saliva retention and saliva composition factors
(Andretta 2005).
El-Hakim reports a modification of this procedure using vascular
clips instead of sutures to ligate the salivary ducts (El-Hakim
2008). This procedure avoids the need for cannulation of ducts,
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thus limiting damage to the duct and avoiding leakage of saliva at
the site of the duct.
(d) Submandibular gland excision. This involves surgical removal
of the submandibular gland(s)which can be removed transorally
(Kauffman 2009), transcervically with a 4 to 6 cm incision in
lateral neck crease approximately 2 to 3cm below the lower edge
of the mandible (Beahm 2009); or endoscopically.
Adverse side effects include xerostomia (dry mouth) with resulting
impact on mastication and dental health; external scarring; and
risk of facial and hypoglossal nerve damage (Burton 1991).
(e) Sublingual gland excision. This involves the removal of the
sublingual gland either unilaterally or bilaterally. Such surgery is
typically carried out in conjunction with submandibular gland
rerouting or excision. It involves extensive floor of mouth resection
and adverse side effects include potentially longer hospital stay,
lingual nerve palsy, and an increased likelihood of developing a
postoperative haemorrhage (Glynn 2007).
(f ) Parotid duct rerouting. This redirects salivary flow in the stim-
ulated state. It involves a general anaesthetic and side effects in-
clude the risk of developing a ranula, possible increase in aspira-
tion (Scully 2009), wound dehiscence (splitting open of wound),
parotitis, and transient parotid swelling (Faggella 1983).
(g) Parotid duct ligation. This procedure involves tying and su-
turing the parotid ducts transorally (El-Hakim 2008). Advantages
are minimal surgical dissection and low morbidity rate (Heywood
2009). Adverse side effects include postoperative wound infection
and risk of developing a ranula
There are combinations of procedures which point to successful
outcomes. Reed 2009 carried out ameta-analysis of surgical proce-
dures used to eliminate or reduce salivary flow . This suggested that
bilateral submandibular gland excision and parotid duct rerouting
pioneered by Wilkie (Wilkie 1977) had a high success rate. Bi-
lateral submandibular gland rerouting and bilateral parotid duct
ligation were also reported to be successful.
(2) Pharmacologic treatments
These interventions work by decreasing the volume of saliva pro-
duced in the oral cavity and in the gastrointestinal tract. In the oral
cavity, agents block cholinergic muscarinic receptors inhibiting
stimulation of the salivary glands. The anticholinergic drugs most
commonly used are atropine, benztropine, glycopyrrolate bro-
mide, benzhexol hydrochloride (also known as trihexyphenidyl)
and scopolamine. Medications vary in their method of delivery,
dosage, frequency of delivery and length of treatment. Medica-
tions can be administered orally, intravenously, topically as dermal
patches, intramuscularly, and via nebulisation (Zeppetella 1999).
Pharmacological interventions cannot selectively block stimula-
tion of the salivary glands. As a result, unwanted side effects which
can involve the central nervous system are frequently reported
(Jongerius 2003).
Side effects from medications include: xerostomia, thick mucoid
secretions, dehydration, urinary retention, urinary tract infections,
constipation, facial flushing, skin rash, fever, dizziness, drowsiness,
headache, dilated pupils, blurred vision, and epilepsy (Mier 2000).
Mier et al. also reported behavioural changes (hyperactivity, rest-
lessness, and irritability).
Gastroesophageal reflux may exacerbate drooling by stimulating
the oesophagosalivary reflex. Antireflux medication decreases gas-
troesophageal reflux, inhibits stimulation of the oesophagosalivary
reflex, and decreases salivary flow (Heine 1996). There are no re-
ports of adverse side effects.
(3) Botulinum toxin
Botulinum toxin A (BoNT-A) is the most common neurotoxin
used to treat drooling. Some researchers have also used Botulinum
Toxin B (BoNT-B) (Berweck 2007; Witherow 2008). Botulinum
toxins act by inhibiting the release of acetylcholine at the neuro-
muscular junction and reducing the amount of saliva produced
by the salivary glands. BoNT-A formulations available include
Botox® (Allergan Inc.) and Dysport® (Ipsen Ltd). Both prod-
ucts differ in terms of molecular structure, manufacturing pro-
cesses and use different methods for determining biological ac-
tivity (Heinen 2006) The dosage varies according to the product
and the weight of the child. One unit of Botox® is estimated to
be comparable to three to four units of Dysport® (Fuster Torres
2007).
Adverse side effects can relate to trauma at the injection site
as well as adverse effects associated with the botulinum toxin
(Reddihough 2010). Adverse effects relating to trauma at the site
of the injection can include pain, hematoma, intraoral blood, swal-
lowing difficulty associated with swelling of the salivary gland,
infection, possible trauma to the facial nerve when injecting the
parotid gland (Reddihough 2010), rash attributed to the ultra-
sound gel when ultrasound is used to identify the site of in-
jection (Hassin-Baer 2005). Side effects associated with the bo-
tulinum toxin include excessively drymouth, problemswith chew-
ing and swallowing as a result of toxin diffusion to muscles in-
volved in swallowing, facial weakness, recurrent mandibular dis-
location (Tan 2001) and transient fever (Ong 2009)
BoNT-B is thought to have a greater affinity to autonomic recep-
tors than BoNT-A. Studies suggest that BoNT-B can be deacti-
vated as a result of antibody formation (Berweck 2007). BoNT-
B is also reported to have a greater impact on xerostomia than
BoNT-A (Tintner 2005). Side effects of BoNT-B include consti-
pation, excessive dry mouth, velopharyngeal incompetence, and
acute parotitis (Tintner 2005; Witherow 2008).
Botulinum toxin varies according to the product selected, the pro-
fessional administering the injections, the dosage of neurotoxin
given, the calibre of the needle used to inject the neurotoxin, the
salivary glands injected, the method used to identify the site of
injection (ultrasound guidance versus blind), the number of injec-
tion points, the type of anaesthesia used in the procedure (general
versus local), and the duration of therapeutic effect. The safe max-
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imum dosage and ideal method of application are not established
(Fuster Torres 2007; Reddihough 2010).
(4) Physical, oro-motor and oro-sensory therapies
These interventions involve correctionof general body posture and
head posture to eliminate the anterior loss of saliva from the oral
cavity, therapy to improve lip and jaw closure as well as increasing
tongue control, reducing tongue thrust (McCracken 1978), nor-
malising tone, and normalising facial and oral sensation. Therapy
can be delivered either individually or in a group (Harris 1980)
and varies according to the level of impairment and the ability
of the child to comply with instructions. There are no reports of
adverse side effects.
(5) Behavioural interventions
These interventions aim to increase target behaviours such as swal-
lowing, wiping, head control, mouth closure, and performing self-
control of drooling behaviour (Van der Burg 2007).
They can be categorised into four different approaches (Van der
Burg 2007): (a) instruction, prompting, and positive social rein-
forcement; (b) negative social reinforcement and declarative pro-
cedures; (c) cueing techniques; and (d) self-management. There
are no reports of adverse side effects.
(6) Intra-oral appliances
These appliances aim to modify and improve oral motor func-
tion, thus improving oral control of saliva and its containment
within the oral cavity. Appliances vary according to shape, posi-
tion within the oral cavity and the length of time that the person
must wear the appliance. Examples of intraoral appliances used in
themanagement of drooling include the Exeter Lip Sensor, palatal
training appliances (Selley 1985) and the Innsbruck Sensorimotor
Activator and Regulator (ISMAR) (Johnson 2004). The Castillo-
Morales appliance (Fischer-Brandies 1987) is used in conjunction
with oro-motor therapy.
Side effects include the inability to tolerate the appliances and oral
discomfort.
(7) Acupuncture
Tongue acupuncture has been used in the treatment of drooling in
children with neurological impairment (Wong 2001). It is based
on traditional Chinese medicine and involves acupuncture per-
formed daily to five points of the tongue for a specified number
of sessions. No side effects are reported.
How the intervention might work
This range of interventions aims to either (1) reduce saliva produc-
tion and/or redirect salivary flow to the posterior part of the oral
cavity; (2) improve physiological oral motor function to increase
containment of saliva within the oral cavity; or (3) increase the
child’s ability to manage oral secretions with behaviours such as
chin wiping, increased frequency of swallowing etc.
Why it is important to do this review
Clinicians currently face the difficult task of selecting an inter-
vention for managing drooling in children with cerebral palsy.
In the absence of a systematic review of the evidence, they must
make clinical decisions against a background of conflicting evi-
dence within the research literature. The long term effects of in-
terventions are unknown.
O B J E C T I V E S
1. To evaluate the effectiveness and safety of interventions
aimed at reducing or eliminating drooling in children with
cerebral palsy.
2. To provide the best available evidence to inform clinical
practice.
3. To assist with future research planning.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We evaluated all published and unpublished randomised con-
trolled trials (RCTs) and controlled clinical trials (CCTs).
We classed as RCTs all trials that involved at least one test treat-
ment aimed at improving or eliminating drooling and one control
treatment; or no treatment with concurrent enrolment and follow
up of the test and control treated groups; as well as trials in which
the treatment to be administered is selected by a random process,
such as a random numbers table (Lefebvre 2008). We imposed no
language restrictions.
We defined CCTs as all trials that involved at least one test treat-
ment aimed at improving or eliminating drooling and one con-
trol treatment; or no treatment with a non-randomised but bias
free method of assigning patients to the test treatment (Lefebvre
2008). We imposed no language restrictions.
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Types of participants
We included male and female children/adolescents aged 0 to 18
years with a clinical diagnosis of any type of CP and all severities of
drooling in this review. We included trials of participants of mixed
ages if the data allowed for data extraction on participants 0 to 18
years. We included trials of participants with other neurological
conditions which included children with CP if the data allowed
for data extraction on participants with CP. We did not exclude
trials on account of additional impairments such as intellectual
impairment, sensory impairment, epilepsy or dysphagia.
Types of interventions
We included any intervention which aimed to reduce or eliminate
drooling. Interventions could occur in any setting and can be
delivered by a trained person or a team. We excluded studies that
involved interventions given by caregiver alone. We considered
any dosages, intensity, mode of delivery, frequency, duration and
timing of delivery of interventions. We considered the immediate,
medium and long term improvements in drooling behaviour as
well as adverse effects of interventions.
We made the following comparisons.
1. Intervention versus no intervention
2. Intervention versus placebo
3. Intervention versus other intervention.
We excluded trials that included the intervention of interest com-
bined with another intervention as these trials would not allow the
reviewers to reach clear consensus on the intervention of interest.
Types of outcome measures
We considered the following outcome measures as potential mea-
sures of success: outcomemeasures that signify a reduction or elim-
ination of drooling and reflect the satisfaction of the person with
CP and/or family with the intervention.
Primary outcomes
1. Reduction of volume of saliva produced
2. Reduction of frequency and severity of drooling
3. Client and/or carer satisfaction with intervention
Secondary outcomes
1. Adverse effects including increase in drooling, dysphagia,
compromised medical health, compromised dental health,
negative social consequences, negative psychological
consequences, hospitalisation, death
2. Change in quality of life, self esteem and self-concept
3. Proxy measures of reduction in unwanted symptoms other
than drooling (e.g. reduction in skin chafing, candida albicans,
odour)
4. Non-compliance with intervention
We considered three time frames: (1) immediate change, (2)
medium term change (three to 18 months) and (3) long term
change (18 months +).
Search methods for identification of studies
We included published and unpublished studies of trials in any
language in the review. There were no date restrictions on trials.
Electronic searches
Weused the search strategy recommended by theCochraneMove-
ment Disorders Group to find relevant studies for the review. We
used search terms and synonyms for ’drooling’, ’cerebral palsy’,
’children’ using the controlled vocabulary used for indexing spe-
cific to each database searched. We imposed limits according to
publication type when allowed by the database and filters to in-
clude clinical trials
We searched the following databases for possible eligible reports
in any language published from inception to December 2010:
: Cochrane Central Register of Controlled Trials (CENTRAL);
Medline via Ovid ; EMBASE; CINAHL; ERIC; Psych INFO;
Web of Science; Web of Knowledge; AMED; SCOPUS; Disser-
tation Abstracts.
We searched for ongoing clinical trials in the Clinical Trials web
site (http://clinicaltrials.gov.) and in the Current Controlled Trials
web site (http://www.controlled-trials.com/).
Searching other resources
We handsearched the following journals.
American Journal of Speech-Language Pathology
Archives of Disease in Childhood
Brain & Development
Clinical Otolaryngology
Clinical Pediatrics
Developmental Medicine and Child Neurology
European Journal of Paediatrics
Folia Phoniatrica et Logopaedica
International Journal of Language and Communication Disorders
International Journal of Paediatric Dentistry
International Journal of Pediatric Otorhinolaryngology
Journal of Communication Disorders
Journal of Developmental and Physical Disabilities
Journal of Intellectual and Developmental DisabilityJournal of Med-
ical Speech-Language Pathology
Journal of Oral Rehabilitation
Journal of Speech, Language and Hearing Disorders
Language, Speech and Hearing Services in Schools
We checked published conference proceedings of the following
organisations.
American Academy of Cerebral Palsy and Developmental
Medicine (2002-2010)
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American Speech and Hearing Association (1999 - 2010)
British Paediatric Neurology Association (1975-2010)
Dysphagia Research Society (1992-2010)
European Academy of Childhood Disability (1988-2010)
European Paediatric Neurology Society (2000-2010)
Royal College of Speech and Language Therapists (1999-2009)
Data collection and analysis
Selection of studies
Wemerged the search results using referencemanagement software
(EndNote) and removed duplicate records of the same report.
Two authors (MWalshe and M Smith) individually examined the
titles and abstracts of studies identified. We classified studies as
’relevant’, ’potentially relevant’, and ’not relevant’ to this review.
We excluded reports that clearly did not meet the inclusion criteria
and were not relevant. We resolved disagreements on inclusion of
studies through discussion.
One author (M Walshe) retrieved full texts of relevant and po-
tentially relevant reports and linked multiple reports of the same
study. All three authors (L Pennington; methodology, M Smith;
content andMWalshe)examined final full texts of relevant reports
for compliance with eligibility criteria. Where the eligibility of a
study was in question, we contacted the authors to seek further
information. The review team were not blinded to information
about study authors, institutions, journal of publication or results.
We resolved any disagreements through discussion. The interrater
reliability for rating the eligibility of studies was found to be Kappa
= 0.8 suggesting substantial agreement (Higgins 2008a).
Data extraction and management
A specifically devised form was used to extract data from study re-
ports. The three review authors (MWalshe, M Smith, and L Pen-
nington) independently extracted data from each report to min-
imise errors and reduce potential risk of bias. Data was extracted
on these four main areas:
• Methods
• Participants
• Interventions
• Outcomes
We resolved disagreements through discussion and on one occa-
sion through consultation with a member of the Cochrane Col-
laboration.
Assessment of risk of bias in included studies
We examined five domains of bias: selection bias, performance
bias, attrition bias, detection bias and reporting bias. ARisk of Bias
table was completed for each study (Characteristics of included
studies) and is summarised in Figure 1,
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Measures of treatment effect
Dichotomous (binary) data
None of the studies included in the review used binary outcomes.
Continuous data
Studies, which reported continuous data, examined reduction of
volume of saliva produced and reduction of frequency and severity
of drooling using different scales. We used the standardised mean
difference (SMD)where possible as a summary statistic to compare
the outcomes for these studies.
Unit of analysis issues
The unit of analysis was individual children. For parallel group
designs (Alrefai 2009; Lin 2008; Reid 2008) we examined whether
the number of measurements in the analysis matched the number
of children that were randomised to that intervention. For cross
over designs (Camp-Bruno 1989; Jongerius 2004a; Mier 2000)
we set out to take all measurements from intervention E (Exper-
imental group) and all measurements from intervention C (Con-
trol group) periods and analyse them as if the trial were a parallel
group trial. For parallel groups, where results were available for
more than one time point, we set out to analyse separately repeated
observations of participants (i.e. short term, medium term and
long term follow-up outcome measures).
Dealing with missing data
The reviewers, whenever possible, contacted authors to supply
any missing data from included studies. Some of the studies were
over 10 years old and although we carried out Internet searches to
locate the authors, we were unable to locate all authors. One of
the authors contacted (Reid 2008) supplied the data on children
with CP in their study. The potential impact of missing data is
dealt with in the Discussion section of the review.
Assessment of heterogeneity
We analysed and present studies for each main category of inter-
vention separately. There is clinical diversity and methodological
heterogeneity within each intervention. There was not sufficient
homogeneity in terms of participants, interventions, and outcome
measures used to perform a meta analysis.
Assessment of reporting biases
Wewere unable to use funnel plots as there were insufficient num-
bers of studies (minimum of 10 required) available. While we can
reduce reporting bias through inclusion of published and unpub-
lished trials, grey literature, and attention to prospective trial reg-
istration, we acknowledge that this is not sufficient to reduce the
risk of reporting bias.
Data synthesis
A meta analysis was not possible. Instead a descriptive summary
of each study was compiled.
Subgroup analysis and investigation of heterogeneity
We grouped the results from each intervention separately. We di-
vided botulinum toxin into subgroups taking into account the
type of botulinum toxin used, the dosage given, the calibre of the
needle used to inject the neurotoxin, the salivary glands injected,
the method used to identify the site of injection, the number of
injection points, and the type of anaesthesia used in the proce-
dure (Table 1). We divided pharmacological interventions into
subgroups according to pharmacological agent used, method of
delivery, dosage, frequency of delivery, and length of treatment
(Table 2).
Sensitivity analysis
We had planned to conduct a sensitivity analysis to examine the
robustness of the review results but this was not possible given
the small numbers of studies retrieved, the heterogeneity within
interventions and themethodological quality of the included trials.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
See Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Nine published studies were retrieved from the electronic searches.
No additional studies were retrieved from hand searching. Two of
the nine published studieswere duplicate reports (Jongerius 2004a;
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Jongerius 2004b) resulting in 8 eligible reports. Two unpublished
trials were located at www.clinicaltrials.gov. The contacts for the
clinical trials were emailed and then telephoned regarding the re-
sults of the clinical trials. The authors of the trials stated that they
were in the process of publishing their results and were unwilling
to provide the reviewers with the unpublished trial results. Data
from the eligible reports were extracted independently by all three
authors. Data from duplicate reports was extracted and collated
on one data extraction form.
Included studies
Following data extraction, only six trials were eligible for in-
clusion in the review (see Characteristics of included studies;
Characteristics of excluded studies). Four studies (Alrefai 2009;
Jongerius 2004a; Lin 2008; Reid 2008) examined the efficacy
of botulinum toxin A (BoNT-A) and two studies (Camp-Bruno
1989;Mier 2000) examined the pharmacological treatments, ben-
ztropine and glycopyrrolate respectively. No RCTs or CCTs were
retrieved on surgical interventions, physical, oro-motor and oro-
sensory treatments, intra-oral appliances, behavioural interven-
tions or acupuncture. Two of the included studies (Camp-Bruno
1989; Mier 2000) did not meet fully the inclusion criteria on age.
These studies also included some participants without CP and did
not allow for data extraction specifically on the children with CP.
The Camp-Bruno study (Camp-Bruno 1989) included adults up
to 44 years. However, 14 of the 20 who completed the study were
children and statistical analysis of the trial results found that age
was not significantly correlated with results from outcome mea-
sures. The review authors decided to include the report in the re-
view as this was the only RCT that examined benztropine, which
is frequently used as an intervention for drooling in children with
CP. One person in this study had a progressive neurological con-
dition and the remainder had CP.Mier 2000 included children up
to 19 years of age and 2 participants who completed the study did
not have CP. This trial explored the efficacy of glycopyrrolate in
the management of drooling and the review authors also decided
to include this study in the absence of any other trials on this in-
tervention. Both trials provided information on the use of these
medications as an intervention with this population.
TRIAL DESIGN
Five of the 6 included studies were RCTs (Alrefai 2009; Camp-
Bruno 1989; Lin 2008; Mier 2000; Reid 2008) and 1 was a CCT
(Jongerius 2004a). Three studies used a parallel design (Alrefai
2009; Lin 2008;Reid 2008) and3used a cross-over design (Camp-
Bruno 1989; Jongerius 2004a; Mier 2000).
SAMPLE SIZE
Approximately 198 participants were recruited in the 6 trials. The
original numbers recruited for Lin 2008 are not available. A total
of 162 people completed the studies. Sample size recruited ranged
from 13 (Lin 2008) to 50 (Reid 2008) (mean 33; SD±12.7 ). The
number of participants completing the studies ranged from 13
to 47 (mean 27; SD ± 12.4). All of the participants in Jongerius
2004a, Alrefai 2009, and Lin 2008 had CP. Thirty one of the 50
children in Reid 2008 had CP, 26 of the 27 people recruited in
Camp-Bruno 1989 had CP and 34 of the 39 children recruited
into the study by Mier 2000 had CP.
SETTINGS
Five of the 6 studies were single centre studies, one was a multi-
centre study. One study was conducted in Taiwan (Lin 2008), one
in Jordan (Alrefai 2009), one in theNetherlands (Jongerius 2004a;
Jongerius 2004b) two in the USA (Camp-Bruno 1989; Mier
2000) and one in Australia (Reid 2008). Four of the studies were
conducted in hospital or health settings (Alrefai 2009; Jongerius
2004a; Mier 2000; Reid 2008) one was conducted in a school
environment (Camp-Bruno 1989) and one setting is unspecified
(Lin 2008).
PARTICIPANTS
The age of participants across all studies ranged from 21 months
to 44 years. Drooling is considered normal in children up to the
age of 18 months and is only considered abnormal in the typically
developing child after the age of 4 years (Fairhurst 2010). Agemust
therefore be considered as a confounding factor, especially when
considering the results of long term outcomemeasures. Four of the
six included studies (Alrefai 2009; Camp-Bruno 1989; Jongerius
2004a; Mier 2000) included children aged 4 years or under. The
lower age range for children in the report by Lin 2008 is unknown.
The youngest population of children was in the study by Alrefai
2009. In this study, children’s ages ranged from 21 months to 7
years with a mean age of 3.5 years. Dental age of children with
CP is considered an important factor with reports that the degree
of drooling decreases as dental age increases (Tahmassebi 2003a)
but is not referred to in any of the included studies.
The type of CP was not specified in any of the studies. All
children recruited in the trials were reported to have mod-
erate to severe drooling. This was determined using defined
criteria on the Teacher Drool Scale (Camp-Bruno 1989) or
Thomas-Stonell and Greenberg Scale (Thomas-Stonell 1988) for
three of the studies (Alrefai 2009; Camp-Bruno 1989; Jongerius
2004a). Camp-Bruno 1989 excluded children with a history of
seizures.The children in the trials were heterogenous in terms of
existing co-morbidities. The children in Mier 2000 had a range
of co-existing disorders and conditions, which included closed
head injury, tracheostomy and hydrocephalus (see Characteristics
of included studies). Jongerius 2004a excluded children with sys-
temic disease (bronchial asthma, congenital heart failure, myas-
thenia gravis). Information on co-morbidities was not provided
for two of the studies (Alrefai 2009; Lin 2008).
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Information on the gender of children recruited as well as the
gender of the children who completed the studies was not available
for all studies. Some studies (Alrefai 2009; Reid 2008; Jongerius
2004a) provide information on gender of children recruited while
others give either no information (Lin 2008) or information only
on those completing the study (Mier 2000; Camp-Bruno 1989).
The gender of the 31 children with CP in the Reid 2008 study
was supplied by the authors. Overall, from the data available, there
weremoremales than females in the trials, reflecting the prevalence
of CP in males (Odding 2006). A total of 86 males and 61 females
were involved in the studies, either at the point of recruitment or
at point of study completion.
INTERVENTIONS
There is considerable variation in how the interventions were de-
livered across all 6 studies.
The four interventions that examined botulinum toxin all used
BoNT - A. The studies varied considerably in the products used,
how these products were prepared, the salivary glands targeted,
the number of injections given and the dosage given, how the
dosage was determined ( i.e. weight dependent), calibre of needles
used for injections, methods used to identify the injection sites
and the anaesthesia given to children during the procedure (see
Table 1). The control interventions also differed. There was similar
heterogeneity in the studies using pharmaceutical interventions
(Table 2).
Treatment ranged from 5 weeks with no follow up (Camp-Bruno
1989) to 22 weeks with 1 year follow-up (Reid 2008)
OUTCOME MEASURES
All studies considered immediate change. The pharmaceutical in-
terventions considered only immediate change. Trials on BoNT-
A examined medium term (three to 18 months) change. None of
the studies in this review considered long term (i.e. 18 months +)
change following intervention.
Primary outcomes
Reduction of volume of saliva produced
Only two studies (Jongerius 2004b, Lin 2008) directly measured
either changes in the volume of saliva produced or changes in
salivary flow following intervention. Jongerius 2004b used the
swab method (Table 3) to measure changes in salivary flow rate.
Lin 2008 measured saliva weight but did not explain how they
measured this.
Reduction of frequency and severity of drooling
All 6 studies measured the frequency and severity of drooling to
some extent. Scales used are described in Table 3. They included
theDroolingFrequency andSeverity Scale (Thomas-Stonell 1988)
the Drooling Quotient (Rapp 1980, Jongerius 2004c), the Drool-
ing Scale (Mier 2000), a visual analogue scale (Jongerius 2004c),
theDrooling Impact Scale (Reid 2008;Reid 2010) and theTeacher
Drool Scale (Camp-Bruno 1989). Four studies (Alrefai 2009;
Camp-Bruno 1989; Reid 2008; Mier 2000) used one outcome
measure for this area, while others (Jongerius 2004a; Lin 2008)
usedmore than one scale. Reid 2008 included just one question on
the frequency of drooling (’How frequently did your child drib-
ble?’) and one question on the severity of drooling (’when your
child did dribble, how severe was the drooling?’) in their assess-
ment. However, they did include other questions that related to
frequency and severity of drooling such as ’How many times a day
did you have to change bibs or clothing due to drooling?’, “How
frequently did your child’s mouth need wiping?”, “How much do
you have to wipe or clean saliva from household items, e.g. toys,
furniture, computers, etc?”,
Reduction in the impact of drooling on child/family
Reid 2008 was the only study that included direct questions on
the impact of drooling on the child and family in their outcome
measure. They asked, ’To what extent did your child’s drooling
affect his or her life?’ and ’To what extent did your child’s dribbling
affect you and your family’s life?’
Client and/or carer satisfaction with intervention
None of the studies included in the review reported outcomes in
this area although Reid 2008 reported that one family was ’fairly’
satisfied with results following BoNT-A and another two ’were
not entirely disappointed’.
Secondary outcomes
Only one of the six included studies (Lin 2008) did not examine
any secondary outcome.
Adverse effects.
Trials used a variety of measures to detect the presence of adverse
effects to treatment.
Reid 2008 asked parents to register perceived side effects of BoNT-
A in a diary. Alrefai 2009 explained the anticipated side effects
of BoNT-A to parents and caregivers and asked them to report
these if they occurred. Jongerius 2004a asked parents to register
all possible side effects of BoNT- A in a diary and discussed these
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during outpatient visits. The extent of side effects was rated on a
4 point scale (0 = ’no side effect’ to 3 = ’severe side effect, con-
stantly present’). Mier 2000 gave parents a list of 15 side effects
of glycopyrrolate and questioned parents every week about these
as well as any other effects not on the list. These adverse effects
were mainly physical and behavioural and were rated on a scale
from 1= ’not at all’ to 4 = “very much’. They also conducted a
physical examination at each visit and checked for the presence of
maceration or induration around the mouth, and checked weight
and blood pressure. ’ In the Camp-Bruno 1989 study, teachers
were asked to report any ’unusual changes’. Nurses also observed
participants for adverse effects and close contact was maintained
with home caretakers regarding side-effects of medication. The
Behavioral and Medical Rating scale (Table 3) was completed two
to three times a week.
Change in quality of life, self-esteem and self-concept.
Only one study included a specific indirect question in this do-
main. In the Drooling Impact Scale, Reid 2008 asked how em-
barrassed the child seemed to be about his/her drooling. None of
the other studies included in the review examined this area.
Proxy measures of reduction in unwanted symptoms other
than drooling (e.g. reduction in skin chafing, candida
albicans, odour).
Reid 2008 included a question on odour in the Drooling Impact
Scale (’ How offensive was the smell of the saliva on your child’?
). They also included a question on skin irritation (”How much
skin irritation has your child had due to drooling?). In general,
measures that examined adverse effects looked for the presence of
new symptoms rather than a reduction in other unwanted symp-
toms that arise as a result of drooling.
Non-compliance with intervention
Compliance with the treatment was reported for all trials except
for Lin 2008.
The methodological quality of the included studies is summarised
in Table 4. Overall the methodological quality of the included
studies is variable. The power to detect a true difference between
intervention groups was not determined for all studies prior to
analysis. Power calculations prior to recruitment were performed
in two of the included studies (Jongerius 2004a; Reid 2008). Lin
2008 had a small number of participants and reports that the
power of the study is reduced to 69.5% as a result. Only two
of the 6 included studies (Jongerius 2004a; Reid 2008) report
the confidence interval of the results. The Risk of Bias (discussed
below) contributes further to the methodological weakness of the
included studies.
Excluded studies
We included any intervention which aimed to reduce or elimi-
nate drooling. We stated in our protocol (Walshe 2010) that we
would exclude studies that involved interventions given by care-
giver alone, or those that included the intervention of interest
combined at the same time with another intervention. However,
we did not come across any trials that used these methodologies.
Studies retrieved were excluded because we were unable to extract
data on children with CP and we were unable to obtain that data
from the authors.
Risk of bias in included studies
See Figure 1 Summary assessments of risk of bias.
Allocation
Methods for recruitment varied. Children were recruited from
either saliva control clinics (Reid 2008), out-patient clinics
(Jongerius 2004a), or local multidisciplinary team CP clinics (
Alrefai 2009). Recruitmentmethods were unclear in Camp-Bruno
1989 study and in Lin 2008. The children in Mier 2000 were re-
cruited through word of mouth and by placing information signs
in examination rooms. Inclusion criteria varied across studies (See
Table 2).
Once recruited, the method of randomisation was unclear for all
but one of the studies (Reid 2008) and selectionbias is likely in all
included studies. In accordance with our protocol (Walshe 2010)
we considered randomisation of participants adequate where a
study applied either a random number table, a computer-gener-
ated random number, coin tossing, dice throwing, selection of
names from an envelope etc. We considered the risk of selection
bias high if participants were selected according to non-random
methods.
We specified that methods of allocation concealment must be de-
scribed in full and that methods of allocation to groups must, as
much as is practical, ensure that participants and researchers did
not foresee the intervention although this may not always be pos-
sible but allocation of trial groups to pharmaceutical interventions
must be adequately concealed from participants and investigators.
The review authors judged that the two interventions included in
this review (pharmacological interventions and botulinum toxin)
could have used allocation concealment methods.
Reid 2008 is the only trial included in the review that describes,
albeit briefly, the method used to conceal the allocation sequence.
The lack of information provided in the other studies make it dif-
ficult for review authors to determine if groups allocated to in-
terventions could have been seen in advance of, or during enrol-
22Interventions for drooling in children with cerebral palsy (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ment. Higgins 2008b advises that adequate concealment of alloca-
tion sequence safeguards those who admit participants to a study
from knowing the upcoming assignments, thus reducing the risk
of selection bias and improving the methodological quality of the
study.
Blinding
As per the protocol (Walshe 2010) performance bias examined
blinding of participants, outcome assessors and data analysts for
pharmaceutical interventions. Performance bias is likely in both
studies involving pharmaceutical interventions (Camp-Bruno
1989; Mier 2000). In Camp-Bruno 1989, the first week on ben-
ztropine was used for drug titration. It is possible that blinding of
the treatment providers and participants could be broken during
this drug titration period. Measures to prevent this are not de-
scribed. In addition, it was not clear if all outcome assessors were
blinded to intervention.
In Mier 2000, there was blinding of the person delivering treat-
ment and patients receiving treatment. However, it is not clear in
the report if the person performing the physical examination for
side effects was blinded to the intervention.
In the protocol (Walshe 2010) it was considered that blinding
of participants and healthcare providers would not be possible
for interventions such as surgery, botulinum toxin, behavioural
interventions, intra-oral appliances, and acupuncture and that we
would examine blinding of outcome assessors and data analysts
in these instances. However, in their study on botulinum toxin,
Alrefai 2009 and Lin 2008 both used a placebo injection and
blinding was possible in both trials.
Overall, the studies included in this review do not clarify who
was and who was not blinded to the intervention. The lack of
clarification on whether outcome assessors were blinded to treat-
ments could therefore introduce observer bias.The results of the
outcomes of these trials may over-estimate the effect of the inter-
vention.
Incomplete outcome data
Incomplete outcome data can suggest attrition bias. For the ma-
jority of studies in this review it is not possible to conclude that
attrition bias is absent in the reporting of the trials. Overall, the
attrition rate for the included studies ranged from 0% (Reid 2008)
to 33% (Alrefai 2009). No attrition is reported in Lin 2008. The
attrition for the pharmacological interventions was high at 26%
(Camp-Bruno 1989) and 31% (Mier 2000). The highest attrition
rate for botulinum toxin was in Alrefai 2009 at 33% contrasting
with Jongerius 2004a which had an attrition of 13% and Reid
2008 at 0%. The lower attrition rate in the latter studies might
be explained by the fact that these studies involved just one dose
injection whereas Alrefai 2009 used two dose injections and with-
drawals occurred at the second injection point. For the majority
of studies in this review it is not possible to conclude that attrition
bias is absent in the reporting of the trials.
We examined completeness of outcome data for each of the in-
cluded studies and examined whether missing data were due to
attrition or exclusion from analysis. Three primary outcomes were
selected for this review: reduction of volume of saliva produced,
reduction of frequency and severity of drooling, and client and/
or carer satisfaction with intervention. The possible impact of in-
complete data is considered for each primary outcome.
Only two studies (Jongerius 2004b; Lin 2008) examined a reduc-
tion of volume of saliva produced. Outcome data for Lin 2008 are
incomplete as there is no information on how many individuals
were initially recruited and whether there were withdrawals from
treatment. Missing outcome data for Jongerius 2004b study are
reported but reasons for the missing data at various measurement
points are not explained. They report 21 missing values and deal
with this missing data by using ’last observation carried forward’
(LOCF). Given that the effects of BoNT-A can decrease over time,
the use of this approach could threaten the validity of the findings.
All six trials reported outcomes for the frequency and severity of
drooling. Lin 2008 report outcome data for this domain but the
lack of information on numbers recruited and attrition makes it
difficult to decide on whether attrition bias exists. The other five
studies report dropouts and withdrawals from treatment but do
not consistently report at what point withdrawal from the study
occurred. Withdrawals are excluded from analysis and in three
studies (Camp-Bruno 1989; Jongerius 2004a; Mier 2000) with-
drawals occurred because of adverse reactions to treatment. It was
difficult for review authors to determine if important outcome
data had been excluded from analysis.
Alrefai 2009 provide outcome data on frequency and severity of
drooling for 16 of the 24 children who received the first BoNT-A
injection. They excluded data for the second BoNT-A injection
from analysis. The caregivers of eight children declined the sec-
ond injection for reasons unexplained. Although 16 children (7
in placebo and 9 in treatment arm) received the second injection
4 months later, the authors performed statistical analysis on the
results of the initial injection only yielding incomplete outcome
data due to exclusion from analysis.
In examining the completeness of outcome data for outcomes on
client and/or carer satisfaction with intervention, only one study
assessed the impact of drooling on children and their families
(Reid 2008). They found a strong statistically significant difference
(p<0.001) in mean scores on the Drooling Impact Scale between
intervention and control groups for children with CP at 1 month.
However, this scale looked at both the degree of drooling and the
impact of drooling and specific information relating to impact is
not available. The difference between groups for children with CP
is not available at 6 months or at 1 year post intervention for the
children with CP but for themain group, which included children
with CP, there was a significant difference between the control and
treatment group at six months.Mean drooling scores did not reach
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their pre-injection levels after one year.While Reid 2008 included
children with other disabilities as well as cerebral palsy and no firm
conclusions can be drawn with respect to effects of BoNT-A at 6
months and one year for children with CP, there is no reason to
consider that this group would respond any differently to children
with intellectual disability.
Outcomes for client and carer satisfaction with interventions are
not available for any of the other included studies.
For the secondary outcomes selected for this review, we also ex-
amined completeness of outcome data for each of the included
studies and examined whether missing data were due to attrition
or exclusion from analysis. Secondary outcomes selected were ad-
verse effects, changes in quality of life, self esteem and self-concept,
proxy measures of reduction in unwanted symptoms other than
drooling (e.g. reduction in skin chafing, candida albicans, odour)
and non-compliance with intervention.
Outcomes for adverse effects reported in trials were largelymedical
and behavioural. The development of adverse effects to either the
therapy or the control resulted in exclusion of participants from
three (Camp-Bruno 1989; Jongerius 2004a; Mier 2000) of the
included studies
Outcomes for adverse effects in most of the included studies relied
on parent /caregiver report. Scant details are provided of mech-
anisms used to elicit reports and observer and reporting bias are
possible. Camp-Bruno 1989 assessed the medical and behavioural
effects more formally but the presence of incomplete outcome
data for dry mouth from 9/20 participants threaten the validity
of results for the physiological side effects of benztropine. Missing
data occurred because it was inadvertently omitted from assess-
ment although included in the Behavioural and Medical Rating
Scale (BMRS).
None of the six included studies set out to measure changes in
quality of life, self esteem and self-concept and none reported on
this outcome.
Selective reporting
Two of the included studies may give rise to concern regarding
reporting bias. One study (Lin 2008) lacks detail in reporting
making it impossible to gauge the overall risk of bias for that
study. The failure of Alrefai 2009 to report on the outcomes for
the second phase of the study also give rise to concerns regarding
reporting bias. The remainder of the studies report on the pre-
specified outcomes.
Other potential sources of bias
The outcome measures used tomeasure the frequency and severity
of drooling in these studies (see Table 3) do not have established
psychometric properties and may contribute to bias in measuring
the response to interventions. The lack of sensitivity of outcome
measures to detect change in drooling behaviour threatens the
validity of study results. Measures that aim to quantify drooling
over time such as the Drooling Quotient is reported to have some
established validity (Jongerius 2004c; Reddihough 2010) and the
content and construct validity of the Drooling Impact Scale along
with test-re-test reliability and its sensitivity to change have been
reported (Reid 2010).
Effects of interventions
See: Summary of findings for the main comparison Summary
of Findings Table; BoNT-A; Summary of findings 2 Summary
of Findings: Pharmaceutical Interventions
The included studies involved two interventions; BoNT-A and
pharmaceutical interventions. (benztropine and glycopyrrolate).
The effects of both interventions are reported separately (see
Summary of findings for the main comparison; Summary of
findings 2). Give the small number of studies for each interven-
tion; four for BoNT-A and two for pharmaceutical interventions,
the methodological flaws and the heterogeneity for all studies, a
meta analysis was not possible.
In estimating the effects of interventions, we made the following
comparisons:
1. Intervention versus no intervention
2. Intervention versus placebo
3. Intervention versus other intervention.
Effect of Botulinum Toxin A
One study (Reid 2008) compared intervention (BoNT-A) with
no intervention. Two compared intervention (BoNT-A versus
placebo (Alrefai 2009; Lin 2008) and one compared intervention
versus another intervention (Jongerius 2004a).
Data for 31 children with CP were provided by Reid 2008. The
mean age of the children with CP was 11.8 years (SD : 12.04
years). They found that changes in degree and impact of drooling
occurred following a single weight dependent dose of BoNT-A
(Botox®, Allergan) into each parotid and submandibular gland.
The reduction in the degree and impact of droolingwas statistically
significant (t = 5.697, p>0.001, mean difference = 27.38, CI for
95% significance = 17.44-37.31) at 1 month post intervention.
Reid 2008 defined a failure to respond to BoNT-A as reduction
of less than 10 points on the Drooling Impact Scale. In the CP
intervention group, the scores on the Drooling Impact Scale for
two children increased by 6 and 12 points respectively suggesting
no response or a negative response to intervention. Five children
with CP had a reduction in scores of 10 to 20 points suggesting a
’mediocre’ response to BoNT-A. The remainder of children in the
intervention group (n =6) had a decrease in scores greater than 20
indicating an improvement in the degree and impact of drooling.
While no follow up data are available specifically on the children
with CP, Reid 2008 state that drooling increased again after 1
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month for the main treated group but that mean drooling scores
did not return to their pre-injection levels even after 1 year.
Alrefai 2009 and Lin 2008 both used a placebo and a parallel
research design. In the Alrefai 2009 study, the mean age of the
participants was 3.5 years in the experimental group ( SD ±1.7
years) and 4.5 years (SD ± 2.0 years) in the control group. They
found a decrease in the frequency of drooling (p= 0.034) and
in the severity of drooling (p = 0.026) one month after 1 dose
of Dysport® was injected into the parotid glands. Dosage was
not weight adjusted. Of note, two of the eleven children in the
treatment experienced an increase in drooling and did not respond
to treatment at one month. Also one child in the placebo group
improved scores on the outcome measure used with a decrease in
frequency scores. The reason for this is unexplained.
Lin 2008 injected a single weight dependent dose of Botox®
(Allergan) into one parotid and the contralateral submandibular
gland. The mean age of children in the study was 14.2 years (SD
± 1.8 years). They found a statistically significant reduction in
drooling frequency and severity at 2 weeks (p= 0.03), 4 weeks (p
= 0.01), 6 weeks (p = 0.04), 8 weeks (p = 0.05 ) and 12 weeks (p
=0.05) following the injection. No difference from baseline was
observed at 10 weeks (p = 0.08) or at 14 (p= 0.08), 18 (p = 0.21)
and 22 (p = 0.28) weeks. The anomaly between the frequency and
severity outcome results for weeks 10 and 12 are unaccounted for
although theDrooling Quotient (DQ) scores (measuring percent-
age of time that a person drools in a specified time period) are
statistically significant for this time period (p = 0.02). Changes in
saliva weight are statistically significant only at 6 weeks (p = 0.02)
and at 12 weeks post injection (p = 0.02). The only period where
scores for the frequency and severity of drooling, DQ scores and
saliva weight scores are all statistically significant is at 6 weeks post
injection. Drooling frequency and severity and saliva weight are
statistically significant at 12 weeks and there is no evidence of an
effect on any outcome measure after that time period.
Jongerius 2004a compared Botox® (Allergan) with scopolamine
patches in a cross over design. Participants were injected with a
single weight dependent dose of Botox® (Allergan) into the sub-
mandibular glands after a trial of scopolamine patches. There was
an intervening washout period of 2-4 weeks. Children recruited to
the study ranged in age from 3-17 years. The mean age of children
was 9.5 years (SD ± 3.7 years). Six of these children withdrew from
the study. The age profile of children completing the study is un-
known. A statistically significant difference in drooling (p < 0.001)
was observed following BoNT-A between baseline measures on
the DQ and measures at 2,4, 8, 16 and 24 weeks. There was also a
statistically significant difference on VAS measures from baseline
to all follow-up assessment points; 2, 4 8, 16 (p < 0.001) and 24
weeks (p = 0.002). Drooling decreased with both the BoNT-A and
scopolamine. There was no significant difference between scopo-
lamine and BoNT-A at 24 weeks on the DQ. Teacher Drool Scale
(TDS) scores were statistically significant at 8 weeks (p <0.001)
and at 24 weeks (p <0.001) post injection. A reduction in salivary
flow (Jongerius 2004b) as measured using the swab method was
statistically significant at 2, 4, and 8 weeks post injection (p<0.05)
but not at 16 and 24 weeks (p>0.05).
There is significant variation amongst these trials making it diffi-
cult to reach a consensus on the efficacy of BoNT-A in the treat-
ment of drooling. Two of the included trials on botulinum toxin
(Jongerius 2004a; Reid 2008) defined what they considered as ’re-
sponders’ to treatment. (Jongerius 2004a, Jongerius 2004b) de-
fined a ’responder’ as one whose baseline score on the DQ de-
creased by 50% and had 2 point improvement on the TDS. On
the swab method (Jongerius 2004b), success was defined as a de-
crease in submandibular salivary flow >1.0 SD within-subjects.
Reid 2008 considered a change of 20 points (1 SD) on the Drool-
ing Impact Scale to be ameaningful response. Lin 2008 andAlrefai
2009 did not define the degree of change on outcome measures
that they considered clinically significant. It is clear that botulinum
toxin does have some effect on the amount of saliva produced and
on the frequency and severity of drooling. Not all children may
respond to a single dose injection (Alrefai 2009; Reid 2008). All
studies showed some statistically significant change for treatment
groups up to 1month post injection. There is insufficient evidence
to form any further conclusions.
The adverse effects to BoNT-A reported were transient in-
crease in drooling (Alrefai 2009), transient flu like symptoms
(Jongerius 2004a), chest infection (Reid 2008) swallowingdifficul-
ties (Jongerius 2004a; Reid 2008) speech difficulties, an increase in
more viscous saliva, and the onset of seizure activity (Reid 2008).
Overall, 18% of the children in Alrefai 2009, 13% in Jongerius
2004a, and 29% in the study reported by Reid 2008 developed
side effects. It is unclear whether all adverse effects reported were
directly related to the intervention. It is unknown if the children
who developed adverse effects in the Reid 2008 study included
childrenwith CP (Summary of findings for themain comparison).
Pharmaceutical Interventions
Both studies on pharmaceutical interventions (Camp-Bruno
1989; Mier 2000) compared intervention versus placebo. They
differed in the medications given and outcome measures used.
Camp-Bruno 1989 examined reduction in salivary flow and found
a statistically significant difference in salivary flow between par-
ticipants (age range 4-44 years) on placebo and those taking ben-
ztropine (p<.001) immediately after intervention.
Both studies examined the frequency and severity of drooling al-
beit usingdifferent outcomemeasures.Camp-Bruno 1989 defined
a ’responder’ as those participants who obtained a mean TDS rat-
ing of less than 3. They also defined ’responsivity’ as a decrease
of one baseline SD or greater. Mier 2000 defined an improve-
ment of 4 points or greater in their 9 point scale as a standard for
significant ’clinical improvement’. On the Teacher Drool Scale,
Camp-Bruno 1989 found a statistically significant difference be-
tween both placebo and intervention in the frequency and severity
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of drooling immediately after intervention (p≤0.001). Mier 2000
using an adaptation of Thomas-Stonell and Greenberg Scale also
found a statistically significant difference between the placebo and
intervention immediately after intervention (p<0.001).
It is unknown how long the effects of these medications lasted in
terms of reducing the quantity of saliva produced and reducing
the frequency and severity of drooling.
Both studies sought information on adverse effects onmedical and
behavioural function.Mier 2000 found that 69% (25/36) children
reported adverse effects while taking glycopyrrolate. The adverse
effects of glycopyrrolate reported were behaviour changes involv-
ing hyperactivity and irritability. Medical side effect reported were
constipation, diarrhoea, dry mouth, dehydration, urinary reten-
tion, urinary tract infection, headache, fever, drowsiness, dizziness,
dilated pupils, blurred vision, facial flushing, rash, nasal conges-
tion, vomiting, dehydration, thickened secretions (in child with
tracheostomy), worsening of epilepsy.
The adverse effects of benztropine reported were behaviour
changes such as irritability and listlessness. Medical side effects
reported were insomnia, vomiting, dilated pupils, disorientation,
facial flushing, ’glassy eyes’ , stomachache, and dry mouth.
Three children of the 27 (11%) children in Camp-Bruno 1989
were excluded because of adverse reactions to benztropine. Eight of
the 39 (20.5%) children in Mier 2000 study dropped out because
of the adverse side effects to glycopyrrolate. As with the trials on
BoNT-A, it is difficult to determine whether all adverse effects
reported were directly related to the medication.
Hospitalisation or death was not reported as an adverse effect of
any intervention.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Outcome Study n Placebo/Exp Mean
Differences
GRADE Comments
Reduction in salivary flow Camp-Bruno 1989 27/27
Cross-over trial.
20 completed the study
Time sampling of drooling be-
haviour as outcome measure
0-2 Weeks
Placebo/Benztropine
Mean difference: 44.8/ 27.4
p≤0.001**
(2 tailed paired t test).
SMD not calculable from data
given
Low No measures beyond immediate effect
Mier 2000 39/39 Cross-over trial.
27 completed the study
Outcome not measured Low No measures beyond immediate effect
Reduction in frequency and
severity of drooling
Camp-Bruno 1989 Teacher Drool Scale as Out-
come Measure
0-2 Weeks
Placebo/Benztropine
Mean difference: 3.53/ 2.38
p≤<0.001**
(2 tailed paired t test).
SMD not calculable from data
given
Low No measures beyond immediate effect
Mier 2000 Adaptation of Thomas-Stonell
& Greenberg Scale as Outcome
Measure
0-4 Weeks Placebo/Glycopyrro-
late
Mean difference 6.33/1.85
P<0.001*
(2 tailed paired t test).
SMD not calculable from data
given
Low No measures beyond this time point
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Adverse effects of benztropine Camp-Bruno 1989 3/27 (11%) withdrew because of
side effects.
Behaviour changes: irritability,
listlessness,
Medical side effects: insomnia,
vomiting, dilated pupils, disori-
entation, facial flushing, ’glassy
eyes’ , stomachache, dry mouth
Low Methodological flaws and risk of bias ( See Table 1)
Adverse effects of glycopyrro-
late
Mier 2000 8/39 (20.5%) withdrew because
of side effects
Behaviour changes: hyperactiv-
ity and irritability,
Medical side effects: constipa-
tion, diarrhoea, dry mouth, de-
hydration, urinary retention, uri-
nary tract infection, headache,
fever, drowsiness, dizziness, di-
lated pupils, blurred vision, fa-
cial flushing, rash, nasal con-
gestion, vomiting, dehydration,
thickened secretions (in child
with tracheostomy), worsening
of epilepsy
Low Methodological flaws and risk of bias ( See Table 1)
Non-compliance with inter-
vention
Camp-Bruno 1989 4/27 (15%) withdrawals Withdrawals because of exces-
sive school absence or children
became ill and parents requested
withdrawal from study
Low
Mier 2000 4/39 (10%) Withdrawals Withdrawals because of failure to
comply or because it was incon-
venient for the families to con-
tinue
Low
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D I S C U S S I O N
Summary of main results
Six RCTs or CCTs were found comparing interventions for drool-
ing in children with CP versus no intervention, placebo or another
intervention. These trials examined only BoNT-A or pharmaceu-
tical interventions. No trials were found on other interventions
such as surgery, behavioural interventions, physical, oro-motor
and oro-sensory therapies, intraoral appliances or acupuncture. All
included trials involved children with moderate or severe drooling
and varied significantly in interventions used and in their method-
ology.
Three of the four trials on BoNT-A used Botox® (Allergan) and
one used Dysport®. All trials reported a positive effect of inter-
vention on the reduction of drooling in childrenwith CP although
some children failed to respond to initial injections of BoNT-A.
Some adverse effects to BoNT-A were reported. Changes in the
frequency and severity of drooling occurred in the placebo groups
for Alrefai 2009 and there was disparity in measures in Lin 2008
that remain unaccounted for. It is suggested that closer scrutiny
should be applied to factors influencing outcomes such as devel-
opmental age of the child and sensitivity and specificity of the
outcome measures used.
The review authors decided to include two trials (Camp-Bruno
1989; Mier 2000) that did not meet strictly the inclusion criteria.
These studies either included a small number of children without
cerebral palsy (Mier 2000) or had some participants who were
were outside the age range (Camp-Bruno 1989) but where age
was not considered an important variable in influencing outcome.
These studies provide valuable data on the use of pharmacological
interventions to control drooling. Both trials used different med-
ications and adverse effects to these medications were reported.
Studies varied in the timing of outcome measurement. Trials on
pharmaceutical interventions examined only the immediate ef-
fects (maximum 4 weeks) of medications, while trials of BoNT-A
examined more medium effects (22 weeks to 1 year). No trials ex-
amined the effects of interventions beyond 12 months. No studies
systematically examined the satisfaction of the child and /or carer
with the intervention or examined the impact of the intervention
on quality of life and psychological well-being of the child and/or
carers.
Overall completeness and applicability of
evidence
No conclusions can be reached on the efficacy and safety of ei-
ther BoNT-A, benztropine or glycopyrrolate in the treatment of
drooling in children with CP. While some evidence is available
for the short-term benefits of both medication and BoNT-A, the
methodological quality and heterogeneity of the included studies
do not allow the review authors to reach any further conclusions
from the studies reviewed.
The populations of children within and across studies varied. Se-
lection bias is likely to affect the results of all included studies. All
children in these trials hadmoderate to severe drooling, which was
often loosely defined. The studies did not include children with
milder problems with drooling. It is acknowledged that children
with CP and mild drooling may not seek interventions such as
surgery or botulinum toxin, but may require some type of inter-
vention. Children varied within and across trials in terms of age,
gender and co morbidities. The type of CP is not provided in any
of the studies. The developmental and dental age of children is
not considered. The findings of the studies cannot be generalised
and no conclusions can be reached on the eligibility criteria of
candidates for these interventions.
The lack of trials on other interventions does not suggest that these
interventions are ineffective. RCTs are not appropriate for some
interventions (e.g. surgery). The fact that fewer adverse effects are
reported for non invasive interventions such as physical, oro-mo-
tor, oro-sensory therapies and behavioural interventions suggest
that rigorous, controlled studies are needed for these interventions.
Despite the increasing popularity of botulinum toxin as an inter-
vention for drooling in childrenwithCP there is no evidence based
consensus on the population of children with CP most suited
to this intervention, the differences between products available,
whether BoNT-A is preferable to BoNT-B in some populations,
the salivary glands most suited for injection, the preparation of the
solution, calculations of ideal dosages, maximum dosage allowed,
the safest method of delivery (calibre of needle, number of injec-
tion sites etc.). Expert opinion suggests the use of ultrasound to
assist in identification of the injection site (Reddihough 2010)..
Quality of the evidence
The authors used the Grades of Recommendations, Assess-
ment, Development and Evaluation Working Group ( GRADE)
(GRADEWorking Group 2004). The quality level of all the body
of evidence across all interventions was rated as ’Low’. The high
likelihood of bias across a number of domains and the presence
of missing data contributed to the downgrading of evidence (see
Figure 1).
Potential biases in the review process
The authors are not aware of any potential biases in the review
process.
Agreements and disagreements with other
studies or reviews
29Interventions for drooling in children with cerebral palsy (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
To the authors’ knowledge, no other reviews have been published
examining all interventions for drooling in children with CP.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to evaluate the effectiveness and
safety of interventions aimed at reducing or eliminating drooling
in children with cerebral palsy or to provide the best available
evidence to inform clinical practice. However, there are a number
of implications for research.
Implications for research
It is acknowledged that not all interventions will lend themselves
readily to RCTs. Although two of the trials in this review (Alrefai
2009;Lin 2008) used a placebo and botulinum toxin, this may
not be permitted by research ethics committees because of the
trauma associated with the placebo injection. Similarly, it might
not be possible to conduct RCTs on some other interventions such
as surgery. In these instances the use of allocation concealment,
blinding of outcome assessors and data analysts should be used.
More research is needed particularly in the area of child / carer
satisfaction and impact of interventions on quality of life
The review emphasises a number of shortcomings that have sig-
nificant implications for the conduct of future trials in this area:
• Firm diagnostic criteria for rating the presence and severity
of drooling must be used and distinctions must be made between
anterior and posterior drooling in accordance with international
consensus statements (Reddihough 2010). This would allow for
a reduction in adverse effects of some interventions for high risk
populations (e.g. rerouting of salivary flow for children with a
history of dysphagia and aspiration)
• Inclusion and exclusion criteria for studies must be clearly
defined to reduce selection bias and children with CP should be
categorised according to the Surveillance of Cerebral Palsy in
Europe (SCPE)(Gainsborough 2008) and the Gross Motor
Function Classification System (GMFCS-E & R) (Palisano
2008). This would allow clinicians to apply evidence to specific
populations of children with CP.
• The developmental age of the child as well as the dental age
of the child should be recorded, as this could be a confounding
variable.
• The intervention and the placebo (if used) should be clearly
described to allow for replication.
• For pharmacological interventions using crossover trial
designs, the washout periods for medications should be
established.
• The presence and severity of all adverse effects of
interventions should be reported to enable investigators to
calculate the number needed to harm, and so that children,
families and carers can make informed decisions on the risks and
side-effects associated with an intervention.
• Psychometrically sound outcome measures must be used.
The use of robust measures that examine not only changes in the
volume, frequency and severity of drooling but the satisfaction of
child and/or carer with the intervention must also be measured.
The impact of the intervention on quality of life and
psychological well-being should be included in studies to
examine the wider impact of intervention.
• The clients should be followed up for at least 18 months to
examine the long term effects of interventions. Follow up should
include examination of adverse effects.
• Longitudinal studies on the effectiveness of interventions
that are pharmacological in nature should be undertaken. Studies
examining the number of botulinum toxin injections, and the
number of repeated doses of medication needed to manage
drooling effectively should be undertaken. These studies should
consider the washout period for these interventions and measure
systematically the adverse effects of repeated botulinum toxin
injections and repeated doses of medications. Measurement of
the client/carer satisfaction with these interventions should be
included in these studies.
• Power calculations should be performed on all studies with
sufficient numbers of children recruited into trails thus avoiding
false negative conclusions.
• Data should be analysed on an ’intention to treat“ basis
• Confidence intervals must be calculated and reported for
the results of outcomes.
• All trials should be reported according to the guidelines set
out in the CONSORT statement (CONSORT 2010)
A C K N OW L E D G E M E N T S
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Thank you to the authors of the included studies who responded
to our queries and to Susan Reid for providing us with unpub-
lished data on children with CP. Thanks to Dr Mike Clarke of
the Cochrane Collaboration for his assistance with our queries on
methodology.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alrefai 2009
Methods Randomised controlled clinical trial. Parallel design. Allocation concealment. Blinding
of person delivering treatment and patients receiving treatment. Outcome measures
taken at baseline and at follow up 1-month after first injection. Second injection given
4 months later with 1-month follow-up
Participants Study conducted inhealth setting in Jordan. 34 children recruited. 26 children completed
the study. Children with severe drooling scores (>/= 7 on Thomas-Stonell and Greenberg
Scale (Thomas-Stonell 1988) only included. Type of CP unknown. Age range: 21
months to 7 years. Mean 3.5 years. 15 boys and 9 girls. Eleven assigned to treatment
group, 13 to control group. Eight did not complete the study (6 from control group and
2 in the intervention group). Co-morbidities unknown
Interventions Treatment Group: BoNT-A. Dysport diluted with normal saline to 20U/0.1cc normal
saline. Parotid glands injected bilaterally. 100 units on first visit, (50 units each gland).
140 units (70 units each gland) on second visit 4 months later. Calibre of needle used:
10mm (30G). No anaesthesia used. Blind method for identifying injection site.
Placebo Group: Saline 0.9%. Method reported to be same as for BoNT
Eight (two from intervention and six from placebo group) declined the second injection
for reasons unknown
Outcomes Frequency and Severity of Drooling (Thomas-Stonell 1988).
Carers/Parents to note presence of possible adverse side effects
User defined 1
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Each patient was given a number and
a registered nurse, independent from the
investigators assigned the patients to the
treatment or placebo group“. Unclear if the
numbers given had a non-random compo-
nent
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of person delivering treatment
and patients receiving treatment. Unclear
if parents/carers taking outcome measures
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Alrefai 2009 (Continued)
were also blinded to the treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk Data on 16 people only provided although
24 received the first injection. No data pro-
vided for outcomes at 4 months
Selective reporting (reporting bias) High risk Aim of the study was to evaluate the effi-
cacy and safety of BoNT for the treatment
of drooling in children with CP, Outcomes
for safety (adverse effects) are reported in-
completely
Other bias Unclear risk Insufficent information to assess whether
an important risk of bias exists
Camp-Bruno 1989
Methods Randomised controlled clinical trial. Crossover design. Report states that study is ’double
blind’. Participants randomly assigned to drug or placebo armof trial. Outcomemeasures
taken at baseline by class room teachers.Observations made by teachers and nurses at one
to two day intervals to guide dose increments of intervention drug in week 1 of 2 week of
intervention period. Teacher Drool Scale (TDS) scores were taken daily and Behavioral/
Medical Rating Scale was completed by the same staff 2 or 3 times a week during the
trial. Research assistant observed drooling behaviour at the same time each day within 1-
4 hours of drug administration. This yielded time sampling data on drooling behaviour
No follow up at the end of the trial.
Participants Study conducted in school setting in USA. 27 participants recruited and 20 completed
the study. People with severe drooling scores (4-5 on Teacher Drool Scale) only included.
Exclusion criteria: People with (1) medical condition contraindicating anticholinergic
medication, (2) receiving neuroleptic medication, (3) history of seizures with or with-
out medication for at least 1 year, (4) history of poor school attendance, (5) living in
households with carers who are unreliable in the administration of medication outside
of school hours
Type of CP unknown. 19 of the 20 participants who completed the study had CP, 1
had an unspecified degenerative central nervous system disease
Age range 4-44 years Mean age not provided. 14 children and 6 adults. 11 male and 9
female. Ten assigned to treatment group either intervention-control or control-interven-
tion group Co-morbidities: More than half were considered to have severe or profound
intellectual disability. No other details on co-morbidities
Interventions Benztropine ’cogentin’ and placebo given for two week period separated by a minimum
of one week ’washout’ period
Treatment group: Initial dose benztropine 0.5 - 1 mg per day depending on participant’s
age and weight. Dosage of benztropine determined in first week of two week trial. Dose
increased at 1-2 day intervals until maximum effect on drooling achieved. Mean dose 3.
8 mg per day. Maximun dose: 6mg. Participants remained on most effective dose (i.e.
TDS ratings of 1-2) in week 2
Placebo Group: 2mg of placebo.
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Camp-Bruno 1989 (Continued)
Both interventions offered as pulverised tablets in soft food once a day on arrival at
school. Caregivers administered at home at weekends
Seven ’eliminated’ from study. Two withdrawn because of excessive school absence, 3
suffered adverse effects to drug, 2 became ill and parents requested their withdrawal from
the study. Unclear at what point these participants were withdrawn from the study
Outcomes Teacher Drool Scale
Behavioral/Medical Rating Scale
Time sampling on observed drooling behaviour ( ’stream’ of drooling and ’bubble’ asso-
ciated with drooling as well as total ’stream’ and ’bubble’ behaviour observed)
Observations by nurse and school staff for side effects
User defined 1
Notes This study involves participants beyond the age limit specified in the protocol and 1
person without CP. Data on the children with CP could not be extracted.The review
authors believe that the person without CP would not significantly influence the results
of the study. Statistical analysis of results found that age was not significantly correlated
with either TDS ratings or total time sampling data scores
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided on the sequence
generation process.
Allocation concealment (selection bias) Unclear risk No information provided to permit judge-
ment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk States that the study is ’double-blind’ . Un-
clear if all staff involved in taking outcome
measures were blinded to intervention. It
is possible that blinding could be broken
during the drug titration period. Measures
to prevent this are not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Seven children ’eliminated’ from the study
but no details given regarding the point at
which they were excluded. Three patients
developed side effects to drug and were ex-
cluded on that basis. No data is provided
for these participants. Data on dry mouth
is incomplete but is addressed
Selective reporting (reporting bias) High risk All pre-specified outcome measures re-
ported for 20 /27 children only
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Camp-Bruno 1989 (Continued)
Other bias High risk Only children with severe drooling in-
cluded in the study.
Jongerius 2004a
Methods Controlled clinical trial, Open label, Crossover design. Sequence of interventions had
fixed order. No allocation concealment. No sequence generation
No blinding of person delivering treatment and patients receiving treatment. Investi-
gators taking Drooling Quotient (DQ) outcome measure blinded. Unclear if parents/
carers taking other outcome measures are blinded
Measures taken: (1) Swab method at baseline, 10th day after scopolamine patch, (con-
trol) and at 2, 8, 16 and 24 weeks after BoNT. (2) DQ at baseline, during the use of
scopolamine, after washout at the end of the scopolamine therapy ( 2-4 weeks after
intervention) after BoNT at 2, 8, 16 and 24 weeks. (3) VAS at baseline, during the use
of scopolamine (exact time points of measurements unknown)and after BoNT at 4, 8,
16, 24 weeks, (4) TDS at baseline and after BoNT injections at 8 and 24 weeks
Participants Study conducted in an outpatient clinic in the Netherlands. 45 children with CP re-
cruited. 39 children completed the study. No details on the children who dropped out
of the study are provided. For the children recruited, the type of CP is unknown; age
range 3-17 years (mean 9.5 years; SD: 3.7); 28 boys 17 girls. Co-morbidities: 34 had
intellectual impairment, 22 had no verbal communication. Presence of epilepsy unclear
but some children on anti-seizure medication
Interventions Treatment: Botox® (Allergan) diluted with 0.9% Sodium Chloride. Submandibular
glands injected bilaterally. Single dose. 15 units per gland for children < 15kg, 20 units
per gland for children between 15kg-25 kg, 25 units for >15kgs. Calibre of needle used:
25G
General anaesthesia used. Ultrasound for identifying injection site.
ControlGroup: Scopolamine patch (Scopo-Dermtis) 1.5 g. Patch placed topically behind
the ear and changed every 72 hours. Duration of patch 10 - 14 days
Six withdrawals: 4 could not fulfil scopolamine patch, 1 change antiepileptic medication,
1 ’intercurrent’ illness
Outcomes Drooling Quotient,
Teacher Drool Scale,
Visual Analogue Scale,
Swab method
User defined 1
Notes Linked with Jongerius 2004b
Risk of bias
Bias Authors’ judgement Support for judgement
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Jongerius 2004a (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information on the allocation
sequence process.
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment.
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding of person delivering treatment
and patients receiving treatment. Investi-
gators taking Drooling Quotient outcome
measure blinded. Unclear if parents/carers
measuring frequency and severity of drool-
ing, Teacher Drool Scale (TDS), Visual
Analogue Scale (VAS) and noting adverse
effects after BoNT were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data adjusted by (1) carrying last observa-
tion forward and (2) by worst-case scenario
system where missing data was replaced
by baseline values. However, there were 6
withdrawals from intervention, 4 because
of reactions to scopolamine patch. It is un-
clear when withdrawals occurred. These
participants were excluded from analysis
Selective reporting (reporting bias) High risk Protocol published and outcomes collected
are reported but it is unclear if all partici-
pants returned for follow-upmeasurements
at 2, 4, 8, 16 and 24 weeks. The study de-
sign required them only to attend for at
least 3 of the 5 visits within the first 24
weeks after the BoNT injection
Other bias High risk Scoplamine delivered before BoNT-A. No
detail provided on stringency of measures
used to ensure that participants did not ex-
hibit carryover effects and had returned to
baseline measures
Both arms of study not treated equally.
TDS not completed while children using
scopolamine. Success of therapy demanded
a ’2-point’ decrease on the TDS’. This was
not a primary measure however and other
measures (DQ and VAS) completed on
both groups
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Lin 2008
Methods Randomised controlled clinical trial. Parallel design. Sequence generation unclear ’ ran-
domly assigned’. Allocation sequence concealment unclear. Blinding of person delivering
treatment group unknown
Unclear if investigators taking outcome measures are blinded. Unclear if children and
carers are blinded to treatment
Outcomemeasures taken 1 week before injections and at, 2,4,6,8,12,14,18 and 22 weeks
after injection. Measures taken at 12 weeks on Frequency and Severity of Drooling
(Thomas-Stonell and Greenberg Scale, 1988) and Drooling Quotient and at 22 weeks
on saliva weight. Method of measuring saliva weight not provided
Participants Study conducted in an unspecified setting in Taiwan.
13 children with CP. Type of CP unknown. Participants had to have severe drooling.
Unclear how this was measured. Seven participants assigned to control group and 6
to treatment group. Age range unknown. Mean age 14.2 years, SD: 1.8 years. Gender
unknown. Co-morbidities unknown
Interventions Treatment Group: Botox® (Allergan). One parotid and contralateral submandibular
gland injected. Calibre of needle used unknown. Type of anaesthesia used unknown.
Ultrasound used for identifying injection site.
Placebo Group: 1.5mls saline given. Method reported to be same as for BoNT. No
withdrawals from treatment reported
Outcomes Frequency and Severity of Drooling (Thomas-Stonell and Greenberg Scale, 1988)
Saliva weight (unknown method)
Drooling Quotient
User defined 1
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Authors state ’randomly assigned’ but in-
sufficient information topermit judgement
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk States ’double-blind’. Unknown if person
delivering the intervention, children, car-
ers/parents and persons taking outcome
measures are blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on whether there were
withdrawals from treatment.No adverse ef-
fects reported
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Lin 2008 (Continued)
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment.
Other bias Unclear risk Insufficient information to permit judge-
ment.
Mier 2000
Methods Randomised controlled clinical trial. Cross-over design. Allocation concealment un-
clear. Sequence generation unclear. Blinding of person delivering treatment and patients
receiving treatment. Outcome measures taken at baseline, weekly at the same point
each day - 2 hours after dose for the 8 weeks of intervention. Washout period of 1 week
only. The washout period for glycopyrrolate is unclear. Not clear if person performing
physical examination for side effects was blinded as to intervention. No follow up at the
end of therapy
Participants Study conducted in hospital setting in USA
39 children with neurological impairment recruited. 27 completed the study. 25 of these
children had CP. Type of CP unknown. Age range of group recruited: 4 years 4 months
to 19 years (mean: 10 years 9 months, SD unknown). 18 boys and 9 girls completed
the study, the gender of the group recruited is unknown. Age range of the group who
completed the study is unknown
Co-morbidities of recruited group: closed head injury, 2 children had tracheostomy, 1
each had Smith-Lemli-Opitz syndrome, partial trisomy 22, congenital toxoplasmosis,
and spinal muscular atrophy. Children also had autism, fetal alcohol syndrome, hydro-
cephalus, congenital heart disease, hypothyroidism, retinitis pigmentosum. One child
with tracheostomy did not complete the study
Interventions Treatment: Glycopyrrolate; Powder form of commercially available glycopyrrolate,
ground up and appropriate dosage placed in capsule by pharmacist. Children < 30kgs
commenced on 0.6mg increasing weekly to 1.2mg, 1.8mg, and 2.4mg. Children >30kgs
began at 1.2mg, increasing weekly to 1.8mg, 2.4mg and 3.0 mg. Drug given orally. If
children unable to swallow capsule, capsule opened and powder placed in food
Dose given three times daily in morning, early afternoon and evening. Four children had
drug administered twice rather than three times daily at parents’ request
Placebo: lactose powder or cellulose prepared and given as glycopyrrolate
12 withdrawals from treatment 8 children withdrew from adverse effects to medication;
1 while receiving the placebo. 4 failed to comply with the protocol
Outcomes Frequency and severity of drooling scale (adaptation of Thomas-Stonell and Greenberg
Scale, 1988)
Physical examination at each visit to note any medical or physical side effects
Carers/Parents to note possible adverse side effects from list of 15 given as well as any
additional side effects
User defined 1
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Mier 2000 (Continued)
Notes Age range of children recruited to the study exceeds 18 years (19 years), Age range of the
children with CP who completed the study is unknown. Two children who completed
the study did not have CP but did have neurological impairment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear. States ”each child was assigned
randomly to either the drug or placebo
treatment arm“
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of person delivering treatment
and patients receiving treatment. Not clear
if person performing physical examination
for side effects was blinded as to interven-
tion
Incomplete outcome data (attrition bias)
All outcomes
High risk Data from 12 children who commenced
the study were not included in the final
analysis. No outcome measures provided
for these 12 children
Selective reporting (reporting bias) High risk Reported outcomes only on the children
who completed the study
Other bias Unclear risk Parents indicated that they know when
their child was receiving glycopyrrolate
because of the dramatic improvement in
drooling
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Reid 2008
Methods Randomised controlled trial. Open label, parallel design. Allocation concealment. Se-
quence generation
Inclusion criteria: age 6-18 years, have a significant problem with drooling ( ’significant’
not defined), parents/carers able to understand study requirements and consent to study
Excluded from the study were children who any of the following: BoNT-A previously
to salivary glands, previous saliva control surgery, any BoNT-A in past 6 months, unfit
for general anaesthesia, unwilling to withhold oral anticholinergic medication for the
length of the study and family history of poor compliance
Drooling Impact Scale measuring the degree and impact of drooling for child over
previous week. taken at baseline and 1 month post injection, at monthly intervals from
2-6 months and at 1 year for treatment group and 1 month post baseline for controls
Participants Multi-centre trial carried out in hospital setting in Australia
50 children with neurological disorders, 31 children with CP. Data on children with CP
provided by authors. Type of CP unknown.
Eighteen children with CP assigned to control group and 13 children with CP to treat-
ment group. Age range: 6-18 years. Mean age 11.8 years. SD: 12.04 years
20 males, 11 females. Co-morbidities for this group (e.g. intellectual impairment,
epilepsy, dysphagia etc.) unknown
Interventions Treatment Group: Botox® (Allergan) diluted with 4ml normal saline. Bilateral sub-
mandibular and parotid glands injected
One dose with 25 units per gland (1ml into centre of each salivary gland) 4 units /kg if
patient’s weight less than 25kgs
Calibre of needle used unknown. General anaesthesia used. Ultrasound used for identi-
fying injection site.
Placebo Group: No treatment. Two withdrawals before intervention, after randomisa-
tion. Both allocated to treatment group. Unclear if these children have CP
Outcomes Drooling Impact Scale
Shortened version of the Drooling Impact Scale
Diary kept by parents of children in treatment group were asked to register any perceived
effects of the injection in the diary
User defined 1
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’a set of random numbers was produced
electronically in two blocks to allowmatch-
ing to 56 consecutive study participants’
Allocation concealment (selection bias) Low risk ’The randomisation schedule was kept cen-
trally by the study monitor; it remained
concealed from all other study personnel
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Reid 2008 (Continued)
until after the groups had been assigned’
Blinding (performance bias and detection
bias)
All outcomes
High risk Person delivering treatment not blinded.
Children and parents, carers not blinded to
intervention. Investigators taking outcome
measures not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcome measures taken at baseline and
1 month post injection for intervention
or 1 month post baseline for controls, at
monthly intervals from 2-6 months and at
1 year for treatment group. Outcome mea-
sures for baseline and 1 month post base-
line for CP group only available to review
authors
Selective reporting (reporting bias) High risk No outcomes available at 2-6 months and
at 1 year for this sub group of children with
CP
Other bias Low risk Measurement bias as no placebo treatment
provided.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Lewis 1994 Ten developmentally delayed children with excessive drooling participated in this study. It was not possible to
extract data on children with cerebral palsy
Mato 2010 Eleven of 30 participants had cerebral palsy. Unable to extract the data on children with cerebral palsy. Authors
contacted but without response
Shionogi Pharma 1 Trial coordinators contacted. Unable to provide review authors with data on children with cerebral palsy until
after publication
Shionogi Pharma 2 Trial coordinators contacted. Unable to provide review authors with data on children with cerebral palsy until
after publication
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Table 1: Characteristics of methods used for treatment in studies examining BoNT-A.
Study Product
used
Glands in-
jected
Injection
dosage
Cali-
bre of nee-
dle used
Anaesthe-
sia used
Method
used
to identify
injection
site
Person ad-
min-
istering in-
jection
Control
Method
Follow up
Alrefai
2009
Dysport
diluted
with nor-
mal saline
30G No anaes-
thesia
Blind Unknown 0.
9% saline
reported to
be admin-
istered
in the same
way.
Yes, 5
months.
Jongerius
2004
Botox®
(Allergan)
diluted
with 0.9%
NaCl
Subman-
dubular
glands bi-
laterally
Single dose
weight de-
pendant
15 units
per gland
for
children
< 15kg, 20
units per
gland for
children
between
15kg-25
kg,
25 units
for >15kgs.
25G General
anaesthesia
Ultra-
sound
Unknown Scopo-
lamine
patch
(Scopo-
Dermtis)
1.5g.
placed
topically
behind the
ear and
changed
every 72
hours.
Duration
of patch
10 - 14
days
Yes, 24
weeks.
Lin 2008 Botox®
(Allergan)
No dilu-
tion stated.
One
parotid
and one
contralat-
eral sub-
mandibu-
lar gland.
Single dose
weight de-
pendant
2 units per
kg body
weight
into each
gland
Unknown Unknown Ultra-
sound
Unknown 1.
5mls saline
given
reported to
be admin-
istered
in the same
way
Yes, 22
weeks.
45Interventions for drooling in children with cerebral palsy (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Table 1: Characteristics of methods used for treatment in studies examining BoNT-A. (Continued)
Reid 2008 Botox®
(Al-
lergan) di-
luted with
4mls
of normal
saline
Parotid
and Sub-
mandibu-
lar glands
bilaterally
25 units
per gland
or
4 units per
kg if child
weighed
less than
25kgs.
Unknown General
anaesthesia
Ultra-
sound
Unknown No inter-
vention
1 year for
treatment
group only
but data
was not
provided
by
authors for
CP group
Table 2. Table 2 Differences in methods used to deliver the pharmacological intervention
Study Product
used
Length of
treatment
Dosage
given
Dosage regi-
men
Method of
delivery
Person ad-
ministering
drugs
Control Follow up
Camp-
Bruno 1989
Benztropine
(Cogentin)
2 weeks Week
1 taken as
titration
week. Week
2 on dose
estimated to
be most ef-
fective from
week 1
Ini-
tial dose 0.5
- 1 mg de-
pending on
patient’s age
and weight.
Dose in-
creased at 1-
2 day inter-
vals. Mean
dose 3.8 mg
Adminis-
tered
as pulverised
tablets
on arrival at
school.
orally, pul-
verised
tablets in
soft food
Med-
ical staff and
parents,
caregivers at
weekends.
2mg
placebo. No
further
information
No
Mier 2000 Glycopyrro-
late
(commer-
cially avail-
able powder
form in
gelatin cap-
sule)
8 weeks on
treatment
drug
Chil-
dren < 30kgs
began at 0.6
mg increas-
ing weekly
to 1.2mg, 1.
8 mg, and 2.
4mg
Chil-
dren >30kgs
Med-
ication given
in the morn-
ing, early af-
ternoon and
evening.
Four chil-
dren given
dose twice
rather than
Orally. If
children un-
able to swal-
low capsule,
pow-
der placed in
food
Unclear but
parent in-
volved in ad-
ministration
Placebo pre-
pared simi-
larly to treat-
ment using
lactose pow-
der or cellu-
lose in
gelatin cap-
sule
No
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Table 2. Table 2 Differences in methods used to deliver the pharmacological intervention (Continued)
began
at 1.2mg, in-
creasing
weekly to 1.
8mg, 2.4mg
and 3.0 mg
Maxi-
mum dosage
3.0mg
for children
> 30kgs, 2.4
mg for chil-
dren< 30kgs
three times
daily
Table 3. Table 3: Outcome measures used in included trials
Measure Purpose of the Measure Method used in administration Validity and Reliability
Swab method To measure changes in salivary
flow rate
Absorbent cotton rolls are
placed directly at the orifices of
the sublingual, submandibular
and parotid glands for 5 min-
utes. Subjects should be evalu-
ated at the same time of day and
by the same person. The rolls
are removed from the mouth
and weighed. The salivary flow
rate is calculated using the for-
mula: weight of rolls (mgs)/
time of collection (mins) (Jon-
gerius 2004b)
Some efforts to quantify its de-
gree of measurement error. (
Jongerius 2004c) and found to
be low.
Drooling Severity and Fre-
quency Scale (Thomas-Stonell
1988)
To measure the frequency and
the severity of drooling
This 9 point scale is divided
into two sections. The first sec-
tion contains 4 items that re-
late to the frequency of drool-
ing behaviour . A score of 1
= ’never drools’ and 4 = ’con-
stantly drools“. The second sec-
tion relates to the severity of
drooling. A score of 1 = ’dry
(never drools) and 5 = ’profuse
(hands, tray and objects wet).
There are no specific guidelines
on its administration
No
Drooling Quotient (Rapp
1980 Jongerius 2004c)
To measure changes in drooling
behaviour
The Drooling Quotient ( DQ)
is defined as the percentage of
Yes
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Table 3. Table 3: Outcome measures used in included trials (Continued)
time that a person drools in a
specified time period. The pres-
ence or absence of saliva on the
lip or dropping from the chin
is recorded by a trained individ-
ual every 15 seconds during two
ten minute sessions, separated
by a 60 minute break. One ses-
sion observed must be while the
person is concentrating and the
second session must be when
the person is distracted. The
person is evaluated in themorn-
ing at least one hour after ameal
while the person is wake and sit-
ting upright. The mean of the
two observations is mapped on
a numeric scale to provide an
outcome measure. Response to
treatment is taken as a 50% re-
duction from baseline values
Visual Analogue Scale (VAS)
(Jongerius 2004c)
To measure of the severity of
drooling over a specified time
period
Raters mark the extent of drool-
ing on a 10cm line. There are
no visible subdivisions on the
line. A mark at the left end of
the scale indicates severe drool-
ing. A mark at the right end of
the scale represents no drooling.
Once the scale is marked, the
line is measured in millimetres
on a scale from 0-100. A VAS
score is obtained by measuring
the position of the mark in mil-
limetres from the right end of
the scale (no drooling) to 100
(severe drooling). A reduction
in 2 standard deviations from
the baseline VAS score is con-
sidered clinically significant
No
Teacher Drool Scale (Camp-
Bruno 1989).
To measure the frequency and
severity of drooling
This is a five point ordinal scale
thatmeasures the frequency and
severity of drooling. A rating of
1 indicates ’no drooling’ where
a rating of 5 means ”constant
drooling, always wet’
No
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Table 3. Table 3: Outcome measures used in included trials (Continued)
Drooling Impact Scale (Reid
2008, Reid 2010).
To measure changes in drooling
behaviour and its consequences
This 10 point scale consists
of 10 questions that cover fre-
quency and severity of drool-
ing, odour, skin irritations, fre-
quency of bib changes, impact
on child as well as impact on
carer and family quality of life
The questions relate to drool-
ing behaviour and its conse-
quences over the previous week.
The scores are totaled to give a
numerical rating of impact. The
maximum possible score is 100
Yes (Reid 2010)
Drooling Scale
(Mier 2000).
To measure the frequency and
severity of drooling
This 9 point scale measures fre-
quency and severity of drool-
ing where 1 = “Dry, never
drools” and 9 = “profuse, cloth-
ing, hands, and objects become
wet frequently”
No
Behavioural andMedical Rat-
ing Scale (Camp-Bruno 1989)
To monitor potential medical
and behavioural side-effects of
medication
19 point scale with 8 be-
havioural and 6 physiological
items rated on a 4 point scale. 1
= “Not at all’ to 4= ”Verymuch“
Unknown
Table 4. Table 4: Methodological Quality of Included Studies
Study Randomi-
sation
Blinding of
Assessors
Similarites
of groups at
baseline
Explana-
tion of
with-
drawals
Account-
ing in anal-
ysis of miss-
ing values
Inten-
tion to treat
analysis
Power Descrip-
tion of eli-
gibility cri-
teria
Alrefai
(2009)
B B B C C B B B
Camp-
Bruno
(1989)
B B B A C B B A
Jongerius
(2004a,
2004b)
C B B Crossover
de-
sign. No in-
dication that
children had
returned to
baseline
A A B A A
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Table 4. Table 4: Methodological Quality of Included Studies (Continued)
measures at
the end of
washout pe-
riod
Lin (2008) B B B B B C C C
Mier (2000) B B B Crossover
de-
sign. No in-
dication that
children had
returned to
baseline
measures at
the end of
washout
period. Brief
washout pe-
riod of 1
week
A C B B C
Reid (2008) A C B A Not applica-
ble No miss-
ing values
B A* for main
study group.
Insuffi-
cient power
for children
with CP
A
Key A=Ran-
domisation
methods ex-
plained
B=Ran-
domisation
methods not
explained or
not fully ex-
plained
C=Ran-
domisation
methods not
adequate
A=Assessor
blind at pre
and post test
B=
Blinding not
reported or
not clearly
reported
C=Blinding
methods not
used
A= Baseline
characteris-
tics reported
B=Base-
line charac-
teristics not
reported
C=Base-
line charac-
teristics re-
ported to be
different
A= With-
drawals ac-
counted for
B=Withdr-
wals not re-
ported
C= With-
drawals not
accounted
for
A=Missing
values ac-
counted for
in analysis
B= No miss-
ing values
shown
C=Missing
values
discounted
from analy-
sis
A=Intention
to treat anal-
ysis
B=Intention
to treat anal-
ysis not used
C= Insuffi-
cient infor-
ma-
tion to make
decision
A=
Power calcu-
lation per-
formed and
sufficient
numbers re-
cruited
B=Power
calculation
not reported
C=
Power calcu-
lation com-
pleted
but insuffi-
cient partici-
pants
recruited
A=Charac-
teristcs of all
participants
provided
in terms of
drooling be-
haviour and
other influ-
enc-
ing factors (
e.g. medica-
tions etc.)
B=Charac-
teristcs of all
partic-
ipants only
provided
in terms of
50Interventions for drooling in children with cerebral palsy (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Table 4: Methodological Quality of Included Studies (Continued)
drooling be-
haviour
C=Charac-
teristics not
clear
WH A T ’ S N E W
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